

Copyright
by
Zane Martin
2011

The Dissertation (or Treatise) Committee for Zane Martin Certifies that this is the approved version of the following dissertation (or treatise):

**Alpha Synuclein Oligomers in Human Pathology:
Significance of Nitrative Alpha Synuclein Modifications**

Committee:

Giulio Tagliatela Ph.D., Supervisor

Kelly Dineley Ph.D.

James Lee Ph.D.

Susan Carlton Ph.D.

Chris Norris Ph.D.

Dean, Graduate School

**Alpha Synuclein Oligomers in Human Pathology:
Significance of Nitrate Alpha Synuclein Modifications**

by

Zane Martin, M.S.

<Dissertation or treatise>

Presented to the Faculty of the Graduate School of
The University of Texas Medical Branch
in Partial Fulfillment
of the Requirements
for the Degree of

Doctor of Philosophy, Neuroscience

**The University of Texas Medical Branch
September, 2011**

Acknowledgements

First and foremost, I want to thank Giulio Tagliatela for his superior mentorship and guidance through this graduate program. I'd also like to thank my committee members for their suggestions, and I am grateful for the members of my lab (past and present): Nicole Bjorklund, Wen-Ru Zheng, and Lindsay Reese for their conversations and expertise leading to scientific explorations. Furthermore, I want to thank the Neuroscience Department (past and present): James Blankenship, Volker Neugebauer, Cindy Cheatham, and Lisa Davis. Finally, I am grateful to my family for supporting and loving me: my husband Rick Martin-Jones, son Dawson Martin-Jones, father Roy Martin, mother Suzanne Shurley Huddleston, and sister Whitney Martin.

Alpha Synuclein Oligomers in Human Pathology: Significance of Nitrate Alpha Synuclein Modifications

Publication No. _____

Zane Martin, Ph.D.

The University of Texas Medical Branch, 2011

Supervisor: Giulio Tagliatela

Abstract:

Intracellular deposition of fibrillar β -sheet aggregates of α Syn is a pathological hallmark of synucleinopathies such as Parkinson disease (PD) and dementia with Lewy bodies (DLB), which are clinically characterized by motor and cognitive dysfunction. Recent evidence indicates that α Syn oligomer intermediates are the most neurotoxic species. However, the mechanism of action of α Syn oligomers remains elusive. Previous studies in our laboratory showed that α Syn oligomers cause increased intracellular calcium, thus promoting activation of protein phosphatase calcineurin and concomitant decrease in transcription factor pCREB, which disrupts synaptic integrity and memory. This phenomenon is observed *in vitro*, *ex vivo*, and *in vivo* and results in deficits in LTP, synaptic plasticity, and memory function. On this basis, I tested the hypothesis that similar effects on synaptic signaling can be observed in human brains from DLB

patients. Here I report that in the brains of DLB patients there is an increase in activated calcineurin (CaN), a significant reduction of pCREB, and this is associated with the appearance of α Syn dimers. Furthermore, I determined the direct toxicity as well as the effect on α Syn oligomers of nitrated α Syn, an oxidative stress-related α Syn modification that has been reported to occur in human synucleopathies. My results show that, as compared to unmodified α Syn, nitrated α Syn elicits no increases in intracellular calcium, shorter LTP expression, and no effects on pCREB levels after sixty minute treatment but decreased cell viability after twenty-four hours. Notably, seeding of unmodified α Syn with small amounts of nitrated α Syn resulted in very stable oligomers that were substantially more toxic than non-seeded α Syn oligomers. Overall these results support the idea that increased CaN activity mediates some of the neuro-dysfunctional effects of aggregated α Syn in humans and may thus constitute a viable pharmacological target. These data also suggest that nitrative modifications of small amounts of α Syn, although not particularly toxic per se, may seed unmodified local α Syn to form stable oligomers that possess increased neurotoxicity. This observation may constitute a molecular mechanism linking oxidative/nitrative insult to synuclein pathology that could trigger a detrimental cascade towards neurodegeneration.

Table of Contents

List of Tables	10
List of Figures	11
Chapter 1: Background	14
Amyloid proteins and amyloid aggregation	14
Cellular pathology of oligomers	16
Calcineurin	18
Protein misfolding diseases	21
Synucleinopathies	21
α Syn (structure and physiological function)	23
α Syn (pathological misfolding/function)	25
α Syn (intracellular vs extracellular)	26
α Syn (posttranslational modifications and pathological significance with emphasis on nitration)	26
Oxidative/Nitrative stress and Synucleinopathies	29
Overall hypothesis and scope of my research	32
Figures	33
Chapter 2: Methods	38
Animals	38
Acetonitrile/HFIP treatment	39
AFM	39
Ca ²⁺ imaging	39
Cell culture	40
Cell viability assay MTS	40
Data Collection and Statistical Analysis	41
Ex vivo rat brain slices	41
Human Tissue	42
ICV injection	42
Immunohistochemistry	43
Nitration using Tetranitromethane	44
Nuclear fractionation	44
Phosphatase Activity Assay	45

Preparation of α Syn oligomers and fibrils	45
SEAP Transfection.....	46
Seeding α Syn with N α Syn	47
Urea/Proteinase K treatment	47
Western blotting.....	48
 Chapter 3: Extracellular alpha synuclein oligomers oppose long term potentiation and impair memory through a mechanism involving calcineurin.....	 48
Abstract.....	48
Introduction	50
Results.....	52
FIGURES.....	55
Discussion	61
 Chapter 4: Soluble alpha synuclein oligomers are associated with reduced pCREB and increased calcineurin in frontal cortex from patients with dementia with Lewy bodies.....	 65
Abstract.....	66
Introduction	69
Results.....	69
FIGURES.....	71
Discussion	78
 Chapter 5: Seeding of alpha synuclein aggregation by nitrated alpha synuclein promotes the formation of stable oligomers with increased toxicity.....	 81
Abstract.....	81
Introduction	82
Results.....	86
FIGURES.....	91
Discussion	97
 Chapter 6: Conclusion	 101

Bibliography	107
Vita.....	121

List of Tables

Table 2.1: Human Tissue Description	43
Table 2.2: Primary antibodies	47

List of Figures

Figure 1.1: Amyloid Aggregation Pathway	33
Figure 1.2: Schematic illustrating the putative role of calcineurin in mediating the synaptic and apoptotic consequences of oligomeric α Syn in the CNS	34
Figure 1.3: α Syn structure and domains	35
Figure 1.4: Three different aggregates of α Syn depending on the environment	35
Figure 1.5: Nitration on Tyr residues is a two-step process.....	37
Figure 1.6: Proposed dityrosine crosslinking of α Syn monomers.....	38
Figure 3.1: α Syn oligomers, but not monomers or fibrils, increases intracellular Ca^{2+} levels in SY5Y cells	60
Figure 3.2 Selective induction of CaN activity and CaN-dependent cell death by oligomeric α Syn in SY5Y cells, organotypic brain slices, and C57 mice	62
Figure 3.3: CREB-promoted transcriptional activity is inhibited by oligomeric α Syn in both basal and AC/PKA-stimulated conditions in SY5Y cells.....	63
Figure 3.4: Oligomeric α Syn reduces pCREB levels in organotypic rat brain slices and wildtype C57 mice	64
Figure 4.1: Immunohistochemistry reveals α Syn aggregates in the DLB frontal cortex that is not seen in age-matched controls	85
Figure 4.2: Increase in dimeric α Syn oligomers	86
Figure 4.3: Truncation (activation) of CaN is increased in the DLB frontal cortex	87

Figure 4.4: Phosphorylation (activation) of CREB is decreased in the DLB frontal cortex	88
Figure 4.5: Immunohistochemistry confirms a reduction of pCREB in the DLB frontal cortex that affects both neuronal and non neuronal cells.	89
Figure 4.6: Levels of α Syn dimers are inversely correlated with levels of pCREB in the DLB frontal cortex.....	90
Figure 5.1: α Syn nitrated by TNM confirmed using Western blot and AFM102	
Figure 5.2: Nitrated α Syn resistant to β -sheet disrupting compounds acetonitrile and HFIP	103
Figure 5.3: Nitrated α Syn has no effect on intracellular Ca^{2+} levels as compared to α Syn oligomers on SY5Y cells	104
Figure 5.4: Nitrated α Syn shortens duration of LTP expression but has no effect on pCREB levels after sixty minutes	104
Figure 5.5: Seeding α Syn with NaSyn (1:10 NaSyn: α Syn) and stirred 5 days leads to different structure from α Syn stirred alone 5 days .	105
Figure 5.6: Nitrated α Syn show decreased cell viability after twenty-four hours, but Nseeded most toxic.....	106
Figure 5.7: 4 and 2 μ M Nseeded α Syn causes release of fura-2 from cells while 1 μ M Nseeded shows no increase in intracellular Ca^{2+} on SY5Y cells.....	106

Chapter 1: Background

Preface

Lewy Bodies (LB) are intracellular proteinaceous deposits that are composed primarily of aggregated alpha-synuclein (α Syn) and are hallmarks of synucleinopathies such as Parkinson disease (PD) and dementia with Lewy bodies (DLB), two terminal neurodegenerative diseases. The clinical symptoms of these disorders involve motor dysfunction (tremor, bradykinesia and rigidity) and in the case of DLB, also involve cognitive symptoms (delirium, visual hallucinations, delusions) similar to Alzheimer Disease (AD), the most common age-associated dementia. While evidence suggests that aggregation of α Syn into toxic oligomeric assemblies plays a central role in the pathogenesis of these disorders, the underlying molecular events remain elusive. With this goal in mind, this project aims at elucidating two molecular aspects associated with the deleterious effects of α Syn on the central nervous system (CNS):

1. Identifying molecular events in diseased human brain that may mediate the detrimental effects of α Syn oligomers.
2. Identifying posttranslational modifications from oxidative/nitrative stress on α Syn that are associated with toxicity through triggering of synuclein-pathology.

The results from these studies characterize a novel pathway centered on CaN and linking synaptic dysfunction with α Syn oligomers. Furthermore, these results provide a link between oxidative/nitrative stress and synucleinopathies.

Amyloid proteins and amyloid aggregation

Amyloid was erroneously characterized as a starch when it was first discovered based on rudimentary iodine-staining techniques, and thus was given the Latin name *amylum*, meaning starch. However, it is now correctly determined that amyloid is actually a macromolecular aggregate of proteins (Osborne, Butler et al. 1979). Amyloid aggregates have common structural features such as 6–10 nm cross β -sheet structures that are parallel, in-register (Chen, Margittai et al. 2007; Margittai and Langen 2008), and can be identified under cross-polarized light after staining with Congo Red (Morgan, Colombres et al. 2004). Amyloid aggregates form through a seeding/nucleation pathway beginning with the misfolding of a natively structured protein.

The amyloidogenic pathway of protein misfolding and aggregation is not completely understood, but kinetic investigations have implied that the critical phase in amyloidogenesis is the development of protein oligomers acting as seeds to accelerate protein misfolding (Harper and Lansbury 1997), which is the foundation for nucleation-dependent aggregation (Gajdusek 1994). Amyloidogenesis begins with a conformational transition into a β -pleat structure followed by nucleation-dependent aggregation after the protein concentration surpasses a threshold known as the critical concentration (Harper and Lansbury 1997). Disaggregation occurs more often than aggregation between monomers during a lag phase in which oligomers are slowly developed, providing an ordered nucleus/template that catalyzes the further elongation into polymers. This growth phase persists until symmetry between monomers and aggregates is obtained (steady-state phase) (Jarrett and Lansbury 1993). Furthermore, the addition of preformed nuclei (seeds) to amyloid monomers can serve as templates for the aggregation reaction, resulting in elimination of the slow stage of primary nucleation. The aggregation pathway then translates into higher-order oligomers and continues with

aggregation into protofibrils, fibrils, and finally deposits (amyloid pathway shown in Figure 1.1).

The different structures in the amyloidogenic pathway have great morphological diversity as revealed using atomic force microscopy (AFM) and electron microscopy (EM). For example, the smaller molecular weight oligomers of α Syn in synucleinopathies have a spherical appearance with heights ranging 2-5 nm while protofibrils resemble chains of spheres with heights ranging 3-7 nm (Conway, Lee et al. 2000). Oligomeric and protofibrillar intermediates have been shown to be the most toxic species. For instance, *in vitro* studies show that α Syn oligomers, unlike monomers or fibrils, are toxic to neural cells (Demuro, Mina et al. 2005)(Martin et al. recently submitted). Furthermore, unlike higher molecular weight fibrils and Lewy body deposit, naturally occurring α Syn oligomers extracted from the brains of α Syn transgenic mice and PD patients demonstrate a correlation between age and disease severity (Sharon, Bar-Joseph et al. 2003). Indeed, recent evidence has shown that the higher weight aggregates might actually be formed as a protection strategy by sequestering the toxic oligomeric intermediates (Olanow, Perl et al. 2004).

Cellular pathology of oligomers

α Syn oligomers are heterogeneous (dimer, trimer, hexamer, protofibril, etc.) and are similar in structure to other oligomers from several neurodegenerative diseases as demonstrated using EM, AFM, and conformational antibodies, (Kayed, Head et al. 2003; Kayed, Sokolov et al. 2004; Demuro, Mina et al. 2005). One intermediate in the amyloidogenic pathway, annular protofibrils, can readily integrate into the cell membrane, perturbing membrane permeability, and causing ion dyshomeostasis such as increased intracellular Ca^{2+} levels (Lashuel, Hartley et al. 2002; Kayed, Head et al. 2003; Zhu, Li et al. 2003; Demuro, Mina et al. 2005; Glabe and Kayed 2006). Indeed,

AFM studies have revealed protofibrils of wildtype and mutant α Syn to be structurally similar to pore-forming bacterial toxins (Ding, Lee et al. 2002; Lashuel, Hartley et al. 2002; Lashuel, Petre et al. 2002). These pore-forming bacteria such as *Staphylococcus aureus* and *Clostridium perfringens* can adopt amphipathic β -sheet oligomers with hydrophobic interior and cationic hydrophilic ends that span the lipid bilayer to form pores in the membrane (Butterfield and Lashuel ; Hotze, Heuck et al. 2002). Both charge and hydrophobic interactions can form between membranes and α Syn oligomers as well (van Rooijen, Claessens et al. 2009). Furthermore, annular protofibrils of α Syn induce leakage from cells only of low-molecular mass molecules no larger than 26 Å while the inner diameter of α Syn annular protofibrils, as observed using EM, is 25 Å, inferring membrane destabilization through a pore-like mechanism (Ding, Lee et al. 2002; Volles and Lansbury 2002). Interestingly, the anti-oligomeric antibody A11 inhibits membrane-permeabilizing activity of both amyloid oligomers and pore-forming toxins, suggesting these similar structures elicit toxicity using similar mechanisms (Kayed, Sokolov et al. 2004; Yoshiike, Kayed et al. 2007). The most direct evidence of the pore-forming mechanism of protofibrils was shown by AFM in reconstituted membranes in which the protofibrils form ion-channel-like structures and elicit single ion-channel currents that lead to ion dyshomeostasis (Quist, Doudevski et al. 2005).

Oligomer induced ion dyshomeostasis such as rises in intracellular Ca^{2+} could profoundly affect neuronal function and eventually cause neuronal death (Volles and Lansbury 2003). Consequently, any neuron type affected by aggregating α Syn (Braak, Del Tredici et al. 2003) can suffer the destabilizing action done on the cell membrane, which may be one common event underlying cognitive and motor symptoms in synucleinopathies. This effect of intracellular Ca^{2+} on neuronal dysfunction caused by the toxic α Syn oligomers could be a target for therapeutic intervention; however, it is not

fully understood which players are involved in oligomeric α Syn induced neurotoxicity. One proposed participant is calcineurin (CaN), a Ca^{2+} -sensitive protein phosphatase abundant in the brain and involved in synaptic plasticity and memory function, as being a key mediator of α Syn oligomer induced synaptic dysfunction and cognitive deficits. CaN is highly abundant in the CNS (Polli, Billingsley et al. 1991), is predominantly localized in the synapse (which is shared by α Syn), and has great influence over synaptic plasticity, memory, and cell death.

Calcineurin

The serine-threonine protein phosphatase CaN, also called protein phosphatase 2B (PP2B) or protein phosphatase 3 (PP3), contains two subunits. The catalytic subunit A has three isoforms (α , β , γ), and the first two (α , β) are highly expressed in the brain and enriched in dendritic spines of neurons (Halpain, Hipolito et al. 1998; Sik, Hajos et al. 1998). Even though subunit A is primarily the catalytic subunit, it also contains the autoinhibitory domain, which is located near the carboxy-terminus downstream of the Ca^{2+} /calmodulin binding domain. The autoinhibitory domain binds in the active-site cleft when Ca^{2+} /Calmodulin is absent, inhibiting the enzyme. Activation of the enzyme occurs in response to increases of intracellular Ca^{2+} , when the binding of Ca^{2+} /Calmodulin causes a conformational change in CaN, exposing the active site (Kissinger, Parge et al. 1995). As a consequence of this Ca^{2+} -dependent activation mechanism, CaN is a critical regulator of Ca^{2+} signaling, synaptic plasticity, learning and memory, and cell survival (Winder, Mansuy et al. 1998; White, Sullivan et al. 2000; Josselyn, Kida et al. 2004; Yang, Omori et al. 2004).

Bcl-2 associated death protein (BAD), a mediator of cell death, is one protein activated through the dephosphorylation of CaN (White, Sullivan et al. 2000; Yang,

Omori et al. 2004). CREB is another protein dephosphorylated directly and indirectly (via activation of protein phosphatase-1, PP-1) by CaN (Winder, Mansuy et al. 1998; Nishi, Snyder et al. 1999; Josselyn, Kida et al. 2004), causing dephosphorylation and inactivation of this transcription factor for key genes involved with synaptic plasticity, long term potentiation (LTP, the cellular basis of learning and memory), and learning and memory, such as FOS and Egr-1 (Mansuy, Mayford et al. 1998; Malleret, Haditsch et al. 2001). PP-1 is normally inhibited by dopamine-and-cyclic-AMP-regulated-phosphoprotein-of-MW-32-kDa (DARPP-32), but dephosphorylation of DARPP-32 by CaN attenuates this inhibition, allowing PP-1 to dephosphorylate substrates involved in synaptic plasticity such as CREB (Nishi, Snyder et al. 1999), AMPA receptors, and NMDA receptors (Morishita, Marie et al. 2005). Just as synaptic function, learning, and memory decrease with age, studies have shown CaN to increase in aged brains (Foster, Sharrow et al. 2001). This is notable because aging is also a primary risk factor in the majority of synucleinopathies. (Figure 1.2 shows a putative cell signaling pathway involving α Syn oligomers perturbing membrane permeability, resulting in increased intracellular Ca^{2+} , followed by CaN activation and dephosphorylation of pCREB, leading to synaptic dysfunction.)

Even though increased CaN is associated with synaptic dysfunction and aging, complete elimination of CaN has revealed similar detrimental outcomes on memory, cognition, and performance as shown using the Morris water maze and other behavioral test paradigms (Mansuy, Mayford et al. 1998; Zeng, Chattarji et al. 2001). In fact, studies involving constitutive or inducible genetic manipulation to increase or decrease CaN have shown contrasting results (Mansuy, Mayford et al. 1998; Malleret, Haditsch et al. 2001; Zeng, Chattarji et al. 2001; Sharma, Bagnall et al. 2003). These discrepancies can be explained by differences in the degree of CaN inhibition. For example, transgenic

animals expressing the CaN autoinhibitory peptide only inhibit 35-40% of CaN whereas a CaN genetic knockout model completely inhibits CaN. This variability could also be caused by other factors such as kinase dysfunction which are known to be positive modulators of learning and memory (CaMKII, CaMKIV, PKC) and are also mediated by Ca^{2+} /Calmodulin, the deciphering switch between phosphatase or kinase activation (Wu, Deisseroth et al. 2001; Mansuy 2003). In view of the fact that both LTP and long-term depression (LTD) are generated through both an increase in intracellular Ca^{2+} and binding to calmodulin seems counter intuitive; however, calmodulin's role has shown to be the bidirectional mediator in synaptic plasticity by activating either phosphatases or kinases depending on calcium concentration (Stefan, Edelstein et al. 2008). It is known that CaN has an increased affinity for calmodulin and is activated at lower calcium concentrations than kinases (Stefan, Edelstein et al. 2008). This is complemented by studies showing high-frequency stimulation results in a Ca^{2+} influx threshold high enough to trigger LTP whereas low-frequency stimulation elicits low concentrations of Ca^{2+} triggering only LTD (Bear 1995; Ni and Chen 2008), demonstrating that low intracellular calcium influx during LTD would allow binding of CaN over kinases. In addition to CaN having increased sensitivity to Ca^{2+} , studies have shown that activated CaN decreases the amount of available calmodulin by dephosphorylating proteins that then bind and suppress calmodulin, such as neuromodulin and neurogranin (Liu and Storm 1989; Seki, Chen et al. 1995). Further evidence of CaN-induced calmodulin suppression is observed decrease in levels of phosphorylated neuromodulin and neurogranin during LTD (Ramakers, Heinen et al. 2000), revealing another link between CaN, LTD, and synaptic dysfunction.

Protein misfolding diseases

Protein misfolding diseases (PMD) encompass a variety of disorders that have a similar mechanism that involves a native monomeric protein structural rearranging to a β -sheet rich ordered conformation (Makin and Serpell 2002), and neurodegenerative diseases (ND) are a subcategory of PMD. These neurological disorders are awfully debilitating, affecting movement and/or cognition. This group of diseases constitute clinically diverse disorders including Alzheimer's disease (AD, amyloid-beta is the amyloid), Synucleinopathies such as Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (α Syn is the amyloid), amyotrophic lateral sclerosis (ALS, SOD1 is the amyloid), Huntington's disease (HD, huntingtin is the amyloid), and transmissible spongiform encephalopathies (TSE, prion is the amyloid) (Martin 2009). Even though these disorders are very diverse clinically, they share a common mechanism of molecular pathogenesis which includes cerebral deposition of insoluble protein deposits, termed amyloid. However, the protein sequence of the misfolded aggregates and the distinct brain regions targeted by these diverse aggregated proteins are different in each of these diseases, leading to clinical differences.

Synucleinopathies

Synucleinopathies comprise an array of neurodegenerative disorders characterized by Lewy Bodies which are insoluble aggregates containing predominantly α Syn protein located in the cytoplasm of neurons and glia. The two most common synucleinopathies are PD and DLB, representing two extremes of motor and cognitive dysfunction, respectively. Even though common clinical features in PD involve motor deficits (bradykinesia, resting tremor, rigidity and postural instability), the term Parkinson

Disease Dementia (PDD) is given to cases in which cognitive impairment is observed in the later stages of PD (Emre 2003). On the other hand, the common clinical characteristics of DLB are cognitive deficits (delirium, visual hallucinations, delusions) while some cases have secondary parkinsonism features; however, the majority of DLB cases develop motor deficits at later stages of the disease (Burn and McKeith 2003). As described, PDD and DLB terminology are derived from the clinical timing of dementia symptoms relative to motor impairments. For example, DLB is described as the development of dementia within one year or less while PDD is a term given when dementia forms over a year after the motor symptoms (McKeith, Galasko et al. 1996). Nevertheless, even though the clinical symptoms in synucleinopathies are distinct at various time-periods during disease, the common thread in the family of synucleinopathies is the misfolding and aggregation of the protein, α Syn.

Further support of α Syn as the etiological player in synucleinopathies were the discoveries of three missense mutations (A53T, A30P, and E46K) in the α Syn protein that are linked to rare forms of familial PD (Polymeropoulos, Lavedan et al. 1997; Kruger, Kuhn et al. 1998; Zarranz, Alegre et al. 2004). Moreover, α Syn is the primary protein component of the lesions (Lewy Bodies) in brains of patients with either PD or DLB; however, the brain regions affected are distinct (Baba, Nakajo et al. 1998). PD synucleinopathies are most prevalent in the substantia nigra with loss of dopaminergic neurons while DLB has most pathogenesis in the basal forebrain with loss of primarily cholinergic neurons (Duda, Giasson et al. 2002). Pathological progression of DLB begins in layers V-VI and progresses into layer III, then finally layer II (Marui, Iseki et al. 2002); however, even though Lewy Bodies are primarily in the basal forebrain in DLB, Lewy body pathology is frequently seen in limbic regions as well (Hurtig, Trojanowski et al. 2000).

Since synucleinopathies are associated with the loss of dopaminergic and cholinergic neurons, the development of dopaminergic replacement therapies (Savitt, Dawson et al. 2006) and acetylcholinesterase inhibitors (Thomas, Burn et al. 2005) have been used as therapeutics and have shown to provide relief of symptoms, albeit only temporary. In view of the fact that these therapeutics are aimed only at increasing neurotransmitter availability, the cause of synaptic dysfunction, α Syn, is overlooked (McNaught and Olanow 2006).

α Syn (structure and physiological function)

α Syn is a randomly folded fourteen-kDa protein composed of three domains: the amphipathic amino-terminus, the hydrophobic core, and the acidic carboxy-terminus (α Syn structure shown in Figure 1.3). The amino-terminus contains seven 11-amino-acid imperfect repeats containing the consensus motif KTKEGV (except one, which is KAKEGV) where α Syn interacts with membrane phospholipids using an amphipathic α -helical conformation (Jo, McLaurin et al. 2000). The middle domain is composed of the hydrophobic core and participates in the formation of β -sheet interactions during amyloid aggregation. Interestingly, the amino acid sequence of α Syn's hydrophobic core is termed non-amyloid- β component (NAC) because this region is also found in amyloid- β plaques from AD patients (Weinreb, Zhen et al. 1996). The carboxy-terminus makes up a disordered conformation and is rich in acidic residues.

Although α Syn is primarily an intrinsically disordered structure, it tends to self-associate through two interactions: 1. charge attraction between the negatively charged carboxy-terminus collapsing around the net positive charge of the amino-terminus, 2. hydrophobic interactions between the hydrophobic core and a hydrophobic cluster region in the carboxy-terminus (Bertoncini, Jung et al. 2005; Dedmon, Lindorff-Larsen et

al. 2005). Experimental evidence has revealed this conformation using small angle x-ray scattering showing the gyration radius of α Syn being ~ 40 Å, which is larger than a globular protein of similar size but smaller than an unfolded protein of similar size (Uversky, Li et al. 2001), demonstrating a partially folded conformation. Also, nuclear magnetic resonance (NMR) studies have shown the existence of intra-molecular interactions between the carboxy tail and residues 30-100 (Bertoncini, Jung et al. 2005). Agents that release these intra-molecular interactions cause an increase in aggregation, and it is therefore thought that these intra-molecular interactions could be a protection strategy against toxic aggregation (Fernandez, Hoyer et al. 2004; Bertoncini, Jung et al. 2005).

α Syn is located in the presynaptic terminal as the former section of the name “synuclein” implies, but not in the nucleus as first described (Maroteaux, Campanelli et al. 1988; Murphy, Rueter et al. 2000). Studies have shown α Syn’s normal function being involved with synaptic vesicle regulation (Murphy, Rueter et al. 2000; Cabin, Shimazu et al. 2002; Larsen, Schmitz et al. 2006), specifically negative regulation of dopamine neurotransmission (Abeliovich, Schmitz et al. 2000) by inhibiting phospholipase D2 (Jenco, Rawlingson et al. 1998; Ahn, Rhim et al. 2002; Outeiro and Lindquist 2003; Payton, Perrin et al. 2004), a membrane-associated enzyme involved in the hydrolysis of phosphatidylcholine which influences cytoskeletal regulation and endocytosis (Brown, Henage et al. 2007). However, inactivation of the α Syn gene does not lead to phenotypic neurodegeneration. Therefore, α Syn loss-of-function most likely does not play a primary role in neurodegeneration (Abeliovich, Schmitz et al. 2000). Instead, a gain-of-function leading to the toxic misfolding and aggregation of α Syn is a more likely etiological component in synucleinopathies.

α Syn (pathological misfolding/function)

α Syn amyloidogenic aggregation occurs primarily through the hydrophobic core but also through the repeats in the amino-terminal half (Serpell, Berriman et al. 2000). The three missense mutations seen in familial PD (A30P, E46K, and A53T) are all located in the amino-terminus region, close to the hydrophobic core. These mutations promote oligomerization using different mechanisms: the A30P mutation decreases helical formation in the amino-terminus, the A53T mutation causes an increase in β -sheet conformation around the site of mutation, and the E46K mutation causes mild helical rearrangement (Bussell and Eliezer 2001; Fredenburg, Rospigliosi et al. 2007). Furthermore, both A30P and A53T mutations interfere with the intra-molecular interactions between the carboxy-terminus and amino-terminus (Bertoncini, Jung et al. 2005). Even though the mutations have variable effects on α Syn, they all promote oligomerization, suggesting oligomerization as a key initiator of neurodegeneration. Furthermore, A53T and A30P mutants have significantly greater membrane destabilization effects, suggesting this mechanism of toxicity by α Syn protofibrils as being a key event in PD pathology (Lashuel, Hartley et al. 2002; Lashuel, Petre et al. 2002; Volles and Lansbury 2002).

Another indicator of intramolecular influences on aggregation kinetics are the different effects after calpain truncation. For example, calpain truncation on preformed α Syn oligomers cleaves oligomers after amino acids 57, 73, 74, and 83, interfering with the fibrillogenic hydrophobic core and inhibiting fibrillation. Conversely, calpain truncation of preformed α Syn fibrils cleaves after residues 114 and 122, accelerating fibrillation (Hodara, Norris et al. 2004; Mishizen-Eberz, Norris et al. 2005). Calpain truncation differences on oligomeric versus fibrillar conformations is a clear demonstration of the conformational differences amongst the different aggregates and reveals that the

hydrophobic core is necessary for fibrillation while the carboxy-terminus is important for fibril inhibition. Studies have shown carboxy-terminal truncations of α Syn leads to increased fibrillation (Li, West et al. 2005), promote nucleation (Hoyer, Cherny et al. 2004), and even seed aggregation of full-length α Syn (Li, West et al. 2005). This is because the carboxy-terminus normally inhibits fibrillation by interacting with the amyloidogenic hydrophobic core.

α Syn (intracellular vs extracellular)

Classically, α Syn aggregates have been described as being intracellular, consistent with α Syn's most abundant localization. However, recent evidence has revealed α Syn aggregates also being extracellularly. For example, evidence to show α Syn's ability to bypass cell membranes is shown by α Syn's presence in the CSF and plasma of PD patients (Borghi, Marchese et al. 2000; El-Agnaf, Salem et al. 2003) as well as studies showing cultured neurons releasing α Syn in the medium (Lee, Patel et al. 2005). Furthermore, fetal tissue grafted into the CNS of PD patients eventually developing α Syn aggregates (Kordower, Chu et al. 2008; Li, Englund et al. 2008), suggesting the possibility of inter-neuronal transmission of extracellular α Syn aggregates (Brundin, Li et al. 2008).

α Syn (posttranslational modifications and pathological significance with emphasis on nitration)

Although the spotlight shines on oligomers as being the most toxic amyloid aggregate in neurodegenerative diseases, recent evidence has shown that not all oligomers share similar characteristics. For example, manipulations on α Syn such as posttranslational modifications can change α Syn's secondary and tertiary structure and hence, function and toxicity. These influential manipulations demonstrate that factors

such as amino acid sequence intertwined with environmental conditions determine which pathway this amyloid will pursue leading to one of three aggregates: amorphous, on-pathway, or off-pathway (the three aggregates are illustrated in Figure 1.4) (Serpell, Sunde et al. 1997; Kodali and Wetzel 2007). Amorphous aggregates are formed spontaneously without any conformational guidelines, causing the protein to immediately precipitate out of solution (Uversky). On the other hand, pathological on-pathway amyloid aggregates form through specific conditions such as increased concentration of α Syn, agitation, increase in temperature, increase in salt, or decrease in pH to cause a monomer to misfold and aggregate through β -sheet interactions to form a nucleus/template during this rate-limiting step termed lag phase (Wetzel, Shivaprasad et al. 2007). These earlier formed α Syn oligomeric species are transient and have high dissociation rates, but once this nucleation-dependent aggregation reaches critical stage in which the association rate exceeds the dissociation rate, amyloid aggregation then increases exponentially and plateaus (Bhak, Choe et al. 2009). α Syn oligomers formed on this pathway disappear as 7-13 nm fibrils begin to form, demonstrating oligomer formation followed by fibril formation on the same pathway (Dobson 1999). However, some oligomeric species are derived from an off-pathway aggregation without a nucleation-dependent lag phase because lack of a high dissociation rate which by overstepping this rate-limiting step leads to a quicker formation of the oligomers (Zhou, Long et al. ; Yamin, Uversky et al. 2003). In addition, because such off-pathway oligomers have increased stability, their further aggregation is greatly reduced and thus formation of fibrils significantly inhibited. Off-pathway oligomers are created through various manipulations to the α Syn protein such as interactions with nicotine or flavinoids, but the present study focuses on posttranslational modifications caused by nitrative and oxidative environments because of the significance of free radical stress to synucleopathic diseases as outlined below.

Under mild oxidizing conditions, methionine residues 1, 5, 116, and 127 are oxidized to methionine sulfoxide. Methionine oxidation causes stable off-pathway oligomers by two mechanisms: 1. stabilizing the intra-molecular hydrophobic interactions between the hydrophobic core and the hydrophobic cluster in the carboxy-terminus and 2. long-range electrostatic interactions between the acidic carboxy-terminus and net positive charge of the amino-terminus (Zhou, Long et al.). Even though methionine oxidation creates stable oligomers that inhibit fibril formation, these oligomers caused during mild oxidization have been shown to be nontoxic to dopaminergic neurons (Zhou, Long et al.).

Under stronger oxidizing conditions such as occurring during neuroinflammation (Gao, Kotzbauer et al. 2008), reactive free radicals like superoxide and the normally neuroprotective nitric oxide are pathologically increased (Huie and Padmaja 1993). During such oxidative and nitrative stress, superoxide and nitric oxide form peroxynitrite, and any of these three reactive species can then extract an electron from tyrosine residues to form very reactive tyrosyl radicals. These tyrosyl radicals then react with nitrative species again and form 3-nitrotyrosine or react with another tyrosyl radical and form *o'o* dityrosine (chemical reaction shown in Figure 1.5) (Koppenol, Moreno et al. 1992; Pfeiffer, Schmidt et al. 2000). Under physiological conditions, dityrosine crosslinking is favored over nitrotyrosine formation because there is decreased availability of nitrogen and oxygen free radicals in comparison to tyrosyl radicals as a result of nitrogen and oxygen free radicals frequently reacting with each other (Pfeiffer, Schmidt et al. 2000).

α Syn contains four Tyr located at residues 39, 125, 133, and 136, and the reactive affinities of these Tyr residues to nitration differ substantially (Bertoncini, Jung et al. 2005; Dedmon, Lindorff-Larsen et al. 2005). For instance, the three Tyr residues in

the Asp and Glu rich carboxy-terminus are highly reactive to nitration due to its high flexibility and polarity (Clayton and George 1999). Tyr 39, on the other hand, lies in the amino-terminus close to the more rigid hydrophobic core and also where lipid membrane-associated α -helices are located, so it is less exposed to solvent, making this Tyr the least reactive to nitration (Hashimoto, Rockenstein et al. 2001; Ruf, Lutz et al. 2008). With this in mind, α Syn in the collapsed formation and nitrative effects primarily on carboxy Tyr would sterically hinder more than two Tyr to react (Ruf, Lutz et al. 2008), favoring dimers. Once sufficient population of covalently formed dimers accumulate, they would form higher molecular weight even-numbered oligomers (Conformation of dityrosine crosslinking of two α Syn monomers shown in Figure 1.6) (Souza, Giasson et al. 2000; Takahashi, Yamashita et al. 2002; Ruf, Lutz et al. 2008).

Oxidative/Nitrative stress and Synucleinopathies

Regardless of their different reactivity, nitration of any of the four Tyr residues of α Syn causes a decrease in helical membrane binding, implying Tyr nitration develops an allosteric structural change on α Syn that can even ameliorate α Syn's normal function on vesicle trafficking (Sevcsik, Trexler et al. ; Hodara, Norris et al. 2004). Aside from nitration effects on α Syn's normal functioning mentioned above, studies on nitration effects on neurodegeneration have been sparse and conflicting. For instance, one recent study has shown using an α Syn fused to an internalization signaling peptide that intracellular nitrated α Syn is more toxic than intracellular non-nitrated α Syn on dopaminergic neurons (Yu, Xu et al.); however, the same authors pointed out that the toxicity was diminished when the internalization tag was removed, so the mechanism of this toxicity doesn't seem to involve membrane instability. Indeed, even though α Syn's most commonly-known mechanism of toxicity is through membrane destabilization (Lashuel, Hartley et al. 2002; Volles and Lansbury 2003), not all α Syn oligomers share

this characteristic (Uversky ; Fink 2006). Nonetheless, other studies have shown nitrate stress as being the mediator between the synergism of environmental stimuli (such as inflammatory-stimulating agents or herbicides) and Tg α Syn animal models (Peng, Oo et al. ; Yu, Xu et al. ; Gao, Kotzbauer et al. 2008). However, since nitrated α Syn oligomers are not β -sheet amyloid aggregates but instead are formed through covalent interactions, the mechanism of nitrated α Syn toxicity may differ from amyloid aggregates and remains unclear.

Much evidence has revealed an association between nitrate/oxidative stress and synucleinopathies. For instance, nitrate stress and synucleinopathy incidences increase with age and both elicit insult on the post-mitotic neurons (Choi, Zhang et al.). Furthermore, it is thought dopaminergic neurons are most susceptible during PD because of the oxidative environment created through dopamine metabolism (Dauer and Przedborski 2003). Moreover, oxidative stress and nitration have also been observed on Lewy body deposits in postmortem PD and DLB brains (Duda, Giasson et al. 2000; Giasson, Duda et al. 2000; Gomez-Tortosa, Gonzalo et al. 2002; Dalfo, Portero-Otin et al. 2005). Despite the association between nitrated α Syn with neurodegeneration in synucleinopathies, the extent of this association is not fully understood.

One fundamental difference between nitrated and non-nitrated α Syn is the covalent interaction during dityrosine crosslinking occurring in the former as compared to nucleation-dependent β -sheet aggregation that characterizes the latter. Indeed, aggregation of nitrated α Syn follows an off-pathway oligomerization that does not lead to fibril formation (Souza, Giasson et al. 2000; Yamin, Uversky et al. 2003; Uversky, Yamin et al. 2005). Moreover, dityrosine crosslinking of nitrated α Syn leads to stable oligomers that are resistant to chaotropic treatments (Souza, Giasson et al. 2000; Norris, Giasson et al. 2003; Uversky, Yamin et al. 2005). Importantly, along with dimer formation,

dityrosine crosslinking can crosslink preformed aggregates as well (Souza, Giasson et al. 2000; Norris, Giasson et al. 2003; Ruf, Lutz et al. 2008). Nitration on preformed aggregates, however, is structurally different from nitration of monomers because aggregates are already in a stacked conformation with the tyrosines freely exposed to solvent (Ruf, Lutz et al. 2008). This explains why nitration on Lewy bodies is observed in postmortem tissue of PD and DLB patients as a consequence of the nitration reaction most likely occurring on already formed aggregates. Nonetheless, no matter what species of α Syn is subject to nitrative stress, covalent crosslinking creates increasingly more stable aggregates.

The increased stability of nitrated oligomers indicates that the secondary structures are different from the non-modified oligomers. However, nitrated and non-nitrated α Syn can still influence each other's aggregation pathway as studies have shown that even substoichiometric amounts of the heterogeneous oligomers created through oxidative and nitrative modifications leads to fibril inhibition of non-modified α Syn (Zhou, Long et al. ; Yamin, Uversky et al. 2003; Uversky, Yamin et al. 2005). Conversely, other studies showed opposing effects after isolation using size-exclusion-chromatography (SEC) of nitrated α Syn monomers and dimers that can actually increase fibrillation by acting as seeds and incorporating into fibrils (Gao, Zhang et al. ; Hodara, Norris et al. 2004). The opposing effects on α Syn aggregation from the different nitrated α Syn species suggests differences in rate constants amongst even the oligomeric species of nitrated α Syn. Moreover, the influences of the nitrated α Syn on α Syn implies that the off- and on-pathways are competitive with each other, and the off-pathway aggregation because of its faster kinetics depletes the concentration of available α Syn to reach critical concentration for on-pathway fibrillation. These substoichiometric effects of nitrated α Syn on α Syn are notable because only a fraction of

α Syn is nitrated during nitrative stress (Hodara, Norris et al. 2004). This suggests that even though not all of α Syn is nitrated during nitrative stress, the fraction that is has a dramatic impact on the unmodified α Syn structure and toxicity due to competitive rate constants, revealing an indirect association of nitrative stress on neurodegeneration based on seeding of α Syn toxic aggregates by trace amounts of nitrated α Syn.

Oxidative stress of other molecules, such as lipids, has also been shown to have an indirect effect on α Syn (Conway, Rochet et al. 2001; Qin, Hu et al. 2007; Choi, Liu et al. 2009; Parihar, Parihar et al. 2009). However, the effects of these oxidized molecules on α Syn are conflicting. For example, one product of lipid oxidation, 4-hydroxyl-2-nonenal (HNE), can form covalent lipid-protein adducts with α Syn. This leads to a conformational change and formation of stable oligomers that are significantly more compact than unmodified α Syn, inhibit fibril formation, and cause marked neurotoxicity on primary mesencephalic cultures (Trostchansky, Lind et al. 2006; Qin, Hu et al. 2007; Smith and Cass 2007; Trostchansky and Rubbo 2007). On the other hand, studies have shown that cholesterol oxidation causes increased fibrillation of α Syn and induces its dissociation from cell membranes (Bosco, Fowler et al. 2006). The interaction of oxidized lipids and α Syn demonstrates another potentially pathologic process by which α Syn interacts with membranes; namely, not only does α Syn interact with anionic lipid head groups on membranes through the basic side-chain α -helices in the amino-terminus during normal function and destabilizes membranes during pathological events such as β -sheet aggregation, but α Syn can also interact with oxidized membranes resulting in pathological aggregates.

Overall hypothesis and scope of my research

I hypothesize that: 1. α Syn oligomers have a significant association with CaN activation and pCREB dephosphorylation in human DLB neuropathology, and 2. Nitration modifications on α Syn potentiates toxicity on non-nitrated α Syn. The scope of this research is to test these hypotheses by pursuing the specific aims of 1. Identifying molecular events in DLB human brains that are not seen in non-diseased individuals but instead correlate to α Syn oligomers and 2. Identifying posttranslational effects on α Syn caused by nitration.

FIGURES




Figure 1.1 Amyloid Aggregation Pathway. Amyloid aggregation pathway starting with a normal protein misfolding into β -sheet conformation, causing nucleation-dependent

aggregation into dimers, higher molecular weight oligomers, protofibrils, and finally deposits.




Figure 1.2 Schematic illustrating the putative role of calcineurin in mediating the synaptic and apoptotic consequences of oligomeric α Syn in the CNS. During the amyloidogenic process of misfolded α Syn, soluble oligomeric intermediates may be formed. Such oligomeric

intermediates increase intracellular Ca²⁺ levels, possibly through cell membrane destabilization. Increased intracellular Ca²⁺ promoted by oligomeric α Syn induces the activity of the Ca²⁺/calmodulin-dependent phosphatase CaN. Active CaN dephosphorylates/*inactivates* CREB and DARPP-32, thus leading to impaired synaptic plasticity that may reversibly cause cognitive, behavioral and even motor deficits in synucleinopathies.




Figure 1.3 α Syn structure composed of three domains. the amphipathic α -helical amino-terminus known to bind phospholipids, the hydrophobic core termed non-amyloid- β component (NAC), and disordered and acidic carboxy-terminus.




Figure 1.4 Three different aggregates of α Syn depending on the environment. The amorphous aggregate is formed spontaneously without any environmental influences, so there are no conformational guidelines. The on-pathway aggregation is nucleation-

dependent with a lagphase because the early formed aggregates have a high dissociation rate; however, once association rate exceeds dissociation, aggregation becomes exponential and plateaus. This aggregation is termed on-pathway because oligomer formation is followed by fibril formation with disappearance of earlier-formed oligomers. Known environmental factors that influence on-pathway aggregates are increased concentration of α Syn, increased temperature, increased salt, or decreased pH. Finally, off-pathway oligomers have the greatest environmental influence, such as oxidation, nitration, nicotine, or flavinoids. Off-pathway oligomers inhibit fibril formation so are off-pathway. Also, because there is not a high dissociation rate of these early formed oligomers, there is no lagphase.




Figure 1.5 Nitration on Tyr residues is a two-step process. First, reactive species extract an electron from tyrosine, causing a highly reactive tyrosyl radical. The tyrosyl radical either reacts with another nitrate radical to form 3-nitrotyrosine or reacts with another tyrosyl radical to form *o,o'*-dityrosine. (Pfeiffer, Schmidt et al. 2000)




Figure 1.6 Proposed dityrosine crosslinking of α Syn monomers. Nitration on the most reactive tyrosines in the carboxy-terminus would cause steric hindrance for more than two tyrosines to react.

Chapter 2: Methods

Animals

Mice on a C57BL/6 background were used for ICV experiments. Male Sprague Dawley rats (150-250 g) were employed for brain slice preparations. Animals were maintained at the UTMB vivarium under USDA standards (12 hr light/dark cycle, food and water *ad libitum*).

At the end of each experiment, animals were sacrificed by exposure to halothane vapors followed by decapitation. Brains were rapidly removed, and either frozen whole (for immunohistochemistry), or dissected into individual areas including hippocampus, cerebellum, frontal cortex, and occipital cortex, then stored at -80°C until further biochemical analyses were performed.

Acetonitrile/HFIP treatment

5 μ l of 90 μ M α Syn, NaSyn monomer, and NaSyn oligomer were individually incubated in 250 μ l of 50% acetonitrile for 10 minutes at RT followed by overnight lyophilization. These samples were then resuspended in 67 μ l HFIP and incubated for 15 minutes at RT and lyophilized overnight. Water and sample buffer were then added followed immediately by western blot analysis.

AFM

For imaging, 5 μ l of \sim 300 μ g/ml of α Syn was adsorbed onto a freshly cleaved mica surface and dried under liquid nitrogen. Samples were imaged in air with a 'home-built' AFM using a Nanotec Scanning Probe Microscope Control System (Dulcinea, Nanotec Electronica) operating in tapping mode, using MSNL cantilevers (0.1N/m, Veeco). Tapping amplitudes were 10-20 nm at the cantilever resonance frequency in air (30-50 kHz). Images were acquired at rates of 60 seconds per image (256 pixels, 2000 nm). Image processing was performed with WSxM software, and standard image processing consisted of flattening and plane subtraction.

Ca²⁺ imaging

SY5Y cells grown on poly-D-lysine coated coverslips were loaded with Fura-2 acetoxymethyl ester (Invitrogen, Carlsbad, CA) according to manufacturer's instruction. Slides were then mounted in a stage containing 1mL of serum-free media. Ca²⁺ imaging was performed on an inverted Nikon Eclipse TE200 microscope with a Nikon S Fluor

20X, 0.75 numerical aperture objective at the Optical Microscopy Core, UTMB-Galveston. The samples were excited with a DG4/DG5 xenon source of illumination at two different wavelengths, 340nm and 380 nm respectively controlled by MetaFluor software (Universal Imaging, Downingtown, PA, USA). The emission was collected using a 71000av2 filter cube from Chroma Technology Corp (Bellows Fall, VT). equipped with a Fura-2 emitter D510/80m.

The experiment was performed at room temperature. After recording the baseline at $t = 5$ min, α Syn was added. 20 μ M of ionomycin was added as a positive control. Ratiometric measurements and calculations were done using MetaFluor software. The trace shown is the 340/380 ratio averaged response of 30 cells after subtraction of background.

Cell culture

Cultured human neuroblastoma SY5Y cells from American Type Culture Collection (ATCC, Manassas, VA) were maintained at 37 °C in a humidified cell incubator under 5% CO₂ atmosphere in T-125 culture flasks containing 10 mL of DMEM/F12 supplemented with 10% heat-inactivated fetal bovine serum (FBS, Sigma, St. Louis, MO). When cultures reached confluence, cells were dislodged using trypsin and divided into two flasks.

Cell Viability assay MTS

This colorimetric assay can be used for determining the number of viable cells in cell growth and cytotoxicity assays through bioreduction by the electron carrier on cells.

Cultured cells were assayed using a commercially available kit (Thermo Fisher) according to manufacturer's instructions.

Data Collection and Statistical Analysis

For Immunohistochemical analyses, equal areas of merged raw digital images were selected from the cortical regions and measured for intensity levels using ImageJ. Microsoft Excel was used for graph production and SPSS Statistics was used for data analysis employing One-way analysis of variance (ANOVA) followed by the Fisher's Least Significant Difference (LSD) test for multiple comparisons. A resulting p value less than 5% ($p < 0.05$) was considered statistically significant. Cumulative data are represented as mean \pm S.E.M.

Ex vivo rat brain slices

According to IACUC-approved protocols, rats were decapitated, the brain was quickly removed and blocked in cold (4 °C) artificial cerebrospinal fluid (aCSF) prepared as follows: 117 mM NaCl, 4.7 mM KCl, 1.2 mM Na_2PO_4 , 2.5 mM CaCl_2 , 1.2 mM MgCl_2 , 25 mM NaHCO_3 , 11 mM glucose, oxygenated and equilibrated to pH 7.4 with 95% O_2 /5% CO_2 . 500 μm -thick hippocampal brain slices were prepared using a Vibroslice (Camden Instruments, London, UK) and equilibrated in aCSF at room temperature for 30 min prior to the addition of test compounds. At the end of the experiments, slices were rapidly frozen in liquid nitrogen and stored at -80 °C until further analyses were performed

Human Tissue

Frozen frontal lobe tissue was obtained through a Materials Transfer Agreement with the Oregon Brain Bank at Oregon Health and Science University in Portland (Table 2.1). Brains are donated by subjects enrolled in studies at the NIH-OHSU Layton Aging and AD center. These cases have post-mortem intervals (PMI) ranging from 3-48 hours and a mean age of 77 years.

Table 2.1 Human Tissue Description

Case#	Diagnosis	Age	Sex	PMI	Braak	α Syn pathology			
						Plaques	Cortex	Amygdala	Midbrain
1720	Healthy	73	Male	5.25	2	1			
1731	Healthy	74	Female	7.5	2	1			
1761	Healthy	86	Male	<24	1	0			
1052	Healthy	87	Male	8	2	1			
1728	Healthy	>89	Female	8	4	0			
198	DLB	72	Male	<24	4	3	yes	yes	yes
727	DLB	76	Female	19	6	3	yes	yes	yes
887	DLB	67	Female	12	5	3	yes	yes	yes
1764	DLB/PD	73	Male	33	2	1	yes	yes	yes
1783	Hippocampal sclerosis/DLB	78	Male	48	2	1	yes	yes	yes

1850	DLB/PD	85	Male	31.5	1	1	yes	yes	yes
1859	DLB/PD	66	Male	3.5	2	0	yes	yes	yes

ICV injection

Using an IACUC-approved protocol, intracerebroventricular (ICV) injections were performed using a modified free-hand method as previously described (Clark, Vivonia et al. 1968; Dineley, Kaye et al. 2010). Briefly, mice were deeply anesthetized with an intraperitoneal injection of ketamine/xylazine mixture (65 and 7.5 mg/kg, respectively), the scalp was shaved and an incision was made through the midline to expose the top of the skull. A 28-gauge needle held with a forceps was lowered 1 mm posterior and 1 mm lateral of the bregma. The needle was connected with 0.28 mm polyethylene tubing to a 25- μ l syringe driven by an electronic programmable micro-infuser (Harvard Apparatus, Holliston, MA), which was used to deliver 3 μ l/mouse at a rate of 6 μ l/min. After injection, the needle was left in place for 1 min and the surgical wound stitched before allowing the mouse to recover while lying on a heated pad under a warm light. Reliability and consistency of injections was routinely tested during actual experiments by injecting India ink in parallel animals and macroscopically observing proper coloration of the ventricles (Dineley, Kaye et al. 2010). 18 h after ICV, animals were given an IP injection of either 1% DMSO in 0.9% saline or CaN inhibitor FK506 diluted in 0.9% saline at 10 mg/kg (LC Laboratories, Woburn, MA).

Immunohistochemistry

Five mm sections of human frontal cortex were taken out of storage at -80°C and equilibrated to -20°C before embedding in Tissue-Tek O.C.T. compound (Sakura Finetek USA, Torrance, CA). 10 µm frontal cortex sections were cut and affixed to Superfrost Plus slides (Thermo Fisher Scientific, Waltham, MA), for storage at -80°C until use. The slides were then rinsed in 0.1M PBS and fixed in ice-cold 4% paraformaldehyde for 15 min in RT. After two washes in 0.1M PBS, the sections were blocked and permeabilized for 1 h in 0.1M PBS containing 10% goat serum, 0.03% Triton-X, and 0.1% phosphatase inhibitor (Thermo Fisher Scientific, Waltham, MA). Incubation with primary antibodies in 0.1M PBS containing 10% serum and 0.1% phosphatase inhibitor was carried out overnight at 4°C. Following two PBS washes, the slides were incubated for 1 h in RT with Alexa Fluor 488 or 594 secondary antibodies (1:600; Invitrogen, Carlsbad, CA) in 0.1M PBS containing 10% serum and 0.1% phosphatase inhibitor. Slides were again rinsed twice in PBS and once in distilled water. Human slides were incubated for 8 min with 0.3% Sudan Black B (EMD Chemicals, Gibbstown, NJ) in 70% ethanol to block lipofuscin autofluorescence (Romijn et al., 1999). After two more rinses in distilled deionized water, Vectashield containing 4',6-diamidino-2-phenylindole (DAPI) was applied (Vector Laboratories, Burlingame, CA), and coverslips were mounted. Nail polish was applied to seal the edges and signal.

Nitration using Tetranitromethane

In the fume hood, 10 µl of 1% TNM in ethanol is added to 100 µl of 1 mg/ml αSyn and stirred for ten minutes. Another 10 µl of the TNM solution is added and stirred again for ten minutes. Then, 30 µl of 8 M urea is added to quench the reaction. Finally, the

reaction is then dialyzed in 20% ethanol in TBS and the solution is exchanged four times to eliminate unreactive TNM.

Nuclear fractionation

Tissue was homogenized and fractionated using a commercially available nuclear/cytosol fractionation kit (BioVision Incorporated, Mountain View, CA, Catalog# K266) according to the manufacturer's instructions.

Phosphatase activity assay

The activity of CaN (PP2B) and combined activity of PP1/PP2A were assayed from lysed cytosolic cell and tissue extracts using a commercially available colorimetric kit (EMD Biosciences, San Diego, CA) according to the manufacturer's instructions.

Preparation of α Syn oligomers and fibrils

The formation of α Syn aggregates (oligomers and fibrils) was achieved via seeding monomeric α Syn with a fractional small amount (1:140 v:v) of amyloid beta ($A\beta$) oligomers (oligomerization described below). The final concentration of contaminant $A\beta$ oligomers in the α Syn solution used in these experiments was 20 to 250 times lower than the minimum $A\beta$ effective concentration. Seed $A\beta$ oligomers were prepared by dissolving 0.3 mg of lyophilized $A\beta$ 42 (W.M. Keck Facility, University of Yale) in 200 μ l of hexafluoro-2-propanol (Sigma-Aldrich) for 10–20 minutes at room temperature. The resulting $A\beta$ solution was added to DD H_2O in a siliconized Eppendorf tube to a final concentration of 66 μ M. A magnetic stir bar was placed in the tube and holes were

placed in the cap to promote evaporation of the HFIP, and the solution was stirred for 48 hours. For preparation of α Syn oligomers of fibrils, 0.1 mg of lyophilized powder of α Syn (rPeptide) was dissolved in 230 μ l H₂O and seeded with the A β oligomers (1:140 v:v) and stirred 20 min for oligomers and 5 days for fibrils. The resulting α Syn aggregates were tested using Western blot for quality control purposes.

Table 2.2 Primary antibodies

<u>Antigen</u>	<u>Antibody and Vendor</u>	<u>Host Species</u>	<u>Dilution</u>
α Syn	4D6; Signet Laboratories Inc.	Mouse	WB -1:5000 IHC – 1:800
α Syn	C-20; Santa Cruz Biotechnology	Rabbit	WB - 1:500
Phospho-CREB (Ser 133)	Anti-pCREB; Millipore	Rabbit	WB - 1:1000 IHC – 1:100
CREB	86B10; Cell Signaling	Mouse	WB - 1:1000 IHC – 1:100
Calcineurin A	610259; BD Biosciences	Mouse	WB - 1:1000
Nitro-synuclein	NSyn; Upstate	Mouse	WB - 1:5000
Nitro-Tyrosine	NTyr; Upstate	Rabbit	WB - 1:10000
Beta Actin	Bactin; Sigma	Mouse	WB - 1:10000
NeuN	NeuN; Cell Signaling	Mouse	WB – 1:1000 IHC – 1:100

SEAP transfection

Transfections were performed using liposome-mediated plasmid introduction in SY5Y cells. The liposome used was DMRIIE-C (Invitrogen, Carlsbad, CA). Cultures at 40% to 50% confluence received 1.2 pmole mL⁻¹ of DNA coupled to DMRIIE-C at a ratio of 1:3, diluted in serum-free OptiMEM medium (Invitrogen, Carlsbad, CA). Three hours after transfection, the liposome-DNA mix was replaced with fresh culture medium with serum and the cells were allowed at least 48 h of recovery prior to addition of α Syn with or without 10 μ M forskolin (Sigma, St. Louis, MO). Secreted alkaline phosphatase activity (SEAP; Clontech, Palo Alto, CA) was used as a direct measure of the effect of test compounds on transcription factor activity. Plasmids containing the SEAP gene coupled to either a control promoter (pTAL-SEAP) or enhancer sequences specific to binding CRE (CRE-SEAP) were transiently transfected as described previously. SEAP activity was assayed directly from the culture medium using the Great EscAPE Chemiluminescent Detection Kit according to manufacturer's instruction (Clontech, Palo Alto, CA).

Seeding α Syn with NaSyn

200 μ l of water is added to a 0.1 mg aliquot of lyophilized α Syn, and the solution is split equally into two different eppendorph tubes. In one of the tubes, 10 μ l of nitrated α Syn monomer (500 μ g/ml) is added and nothing is added to the other tube (this sample will be control fibrils). Both samples are then stirred for five days.

Urea/Proteinase K treatment

100 μ g of 1 mg/ml solution of brain homogenate were treated with 100 μ g/ml proteinase K (PK, Sigma Aldrich #P2308) for 60 minutes at 37°C, whereas a parallel set

of samples were treated with 8 M urea (Sigma Aldrich #U-1250) in boiling water for 20 minutes. The reactions were stopped by adding SDS sample buffer and boiling for 10 minutes. The samples were then resolved on SDS polyacrylamide gels, transferred to nitrocellulose membrane and probed with a rabbit polyclonal anti- α Syn antibody (C-20, Santa Cruz cat# sc-7011-R).

Western blotting

Tissue was homogenized either into nuclear fractions or in lysis buffer containing 50 mM Tris HCl (pH 7.6), 0.01% NP-40, 150 mM NaCl, 2 mM EDTA, 0.1% SDS, 1 mM PMSF, and 1% protease cocktail inhibitors (Sigma, St. Louis, MO). Following homogenizing, the tissue was centrifuged at 20,000 g for 5 min, and the supernatants collected. Protein samples containing 100 μ g of proteins as determined by the BCA assay (Pierce, Rockford, IL), were subjected to SDS-polyacrylamide gel electrophoresis using 10% gels, followed by electrophoretic transfer to nitrocellulose membranes (Biorad, Hercules, CA). Membranes were then incubated overnight at 4°C with the primary antibody, followed by an appropriate horseradish peroxidase (HRP) conjugated secondary antibody (Biorad) against rabbit IgG (for polyclonal primaries) or mouse IgG (for monoclonal primaries). Detection was achieved using Enhanced Chemiluminescence (ECL) (Pierce, Rockford, IL).

Chapter 3: Extracellular alpha synuclein oligomers oppose long term potentiation and impair memory through a mechanism involving calcineurin.

Abstract

Intracellular deposition of fibrillar aggregates of α Syn is a pathological hallmark of such neurodegenerative diseases as PD and DLB, which are clinically characterized by motor dysfunction and cognitive decline. However, recent evidence indicates that small α Syn oligomeric aggregates which precede fibril formation may be the most neurotoxic species and can be found extracellularly where they may be key to inter-neuronal transmission of the disease neuropathology. This new evidence has changed the view of pathological α Syn aggregation from a self-contained cellular phenomenon to an extracellular event and prompted investigation of the putative neurodysfunctional effects of extracellular α Syn oligomers. Here, we examined how oligomeric α Syn affects neuronal function and memory when applied extracellularly. We found that oligomeric α Syn, but not monomeric or fibrillar α Syn, increased intracellular Ca^{2+} levels, induced the activity of calcineurin (CaN), and decreased the activity of CREB in human SY5Y neuroblastoma cells. Similar induction of CaN and inhibition of active pCREB were observed when α Syn oligomers, but not monomers or fibrils, were applied to organotypic brain slices. As well, α Syn oligomers induced CaN and decreased pCREB when acutely injected into the lateral ventricles of wild-type mice. Notably, all these events could be reversed by inhibition of CaN with FK506. These results indicate that extracellular α Syn oligomers can impact neuronal function and produce memory deficits through mechanisms that invoke CaN activity.

Preface

The following experiments were a collective effort done in my lab except Figure 3.4B, which was done independently by me.

Introduction

The signature event in synucleinopathies such as Parkinson's disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy (MSA), is the misfolding, aggregation, and intracellular accumulation of alpha synuclein (α Syn) (Goedert 2001). α Syn is a 140 amino acid long protein that remains relatively unfolded under non-disease conditions and is abundant in pre-synaptic terminals of neurons where it may play a role in vesicular trafficking (Burre, Sharma et al. 2010). α Syn is prone to misfolding and aggregating into fibrils that are the main components of Lewy bodies (LB) and Lewy neurites (Braak et al., 1999 (Spillantini, Crowther et al. 1998; Braak, Sandmann-Keil et al. 1999). These deposits are accompanied by progressive neuronal dysfunction and eventually death of affected neuronal populations (Braak and Del Tredici 2008). Behavioral and cognitive deficits usually accompany these pathological changes (Braak, Rub et al. 2005; Caviness, Lue et al. 2011). The discovery of three missense mutations in the SNCA gene (encoding α Syn) that are linked to rare cases of familial PD (Polymeropoulos, Lavedan et al. 1997; Kruger, Kuhn et al. 1998; Zarranz, Alegre et al. 2004), have highlighted the potential importance of α Syn in the pathogenesis of these diseases, likely due to toxic gain-of-function. Indeed, α Syn knock-out mice are normal, but mice overexpressing α Syn display synucleopathic phenotype (Kahle 2008). However, α Syn fibrils that comprise LBs are thought to be protective on account of their possible sequestration activity of more toxic oligomeric forms of α Syn; oligomeric α Syn is considered an intermediate in the aggregation pathway (Olanow, Perl et al. 2004). α Syn oligomer toxicity is exemplified by a juvenile form of PD, where extensive neurodegeneration occurs even in the absence of LB formation (Takahashi, Ohama et al. 1994; Mori, Kondo et al. 1998; Olanow, Perl et al. 2004). Also, microscopic and biochemical analysis showed that LB-bearing neurons do not exhibit cytotoxicity

(Gertz, Siegers et al. 1994; Tompkins and Hill 1997). More directly, *in vitro* and *in vivo* experiments recently illustrated that α Syn oligomers are toxic to neural cells whereas fibrils are not (Kayed, Head et al. 2003; Putcha, Danzer et al. 2010; Winner, Jappelli et al. 2011). Classically, the aggregation and deposition of α Syn has been considered an intracellular phenomenon (McNaught and Olanow 2006). However, more recent evidence demonstrates the existence of extracellular α Syn oligomers and suggests that they play key roles in disease progression (Lee 2008; Brown 2010). For example, α Syn oligomers are released from cultured cells (Emmanouilidou, Melachroinou et al. 2010), are detectable in the spinal fluid and plasma of PD patients (Borghi, Marchese et al. 2000; El-Agnaf, Salem et al. 2003; El-Agnaf, Salem et al. 2006) as well as in the soluble protein fraction from brains of DLB patients (Paleologou, Kragh et al. 2009). In addition, α Syn can be transmitted from neuron to neuron (Desplats, Lee et al. 2009) or neuron to astroglia (Lee, Suk et al. 2010); fetal tissue grafts in the brain of PD patients acquire LB pathology (Li, Englund et al. 2008; Chu and Kordower 2009); and stem cells or fetal tissue transplanted into the CNS of Tg mice overexpressing human α Syn show intracellular deposits formed by host α Syn (Desplats, Lee et al. 2009; Hansen, Angot et al. 2011). Collectively, these findings suggest the presence of extracellularly released α Syn oligomers. The presence of extracellularly-released α Syn oligomers suggests that they play a central role in synucleinopathic human diseases (Lee 2008). It also illustrates the importance of determining the effects of extracellular α Syn on neurons, and specifically at synapses where α Syn is thought to be released from the α Syn-enriched pre-synaptic terminals (Schulz-Schaeffer 2010). With this goal in mind, the present study used *in vitro*, *ex vivo* and *in vivo* models to investigate the effects of extracellularly-applied α Syn oligomers on Ca^{2+} -related signaling, hippocampal synaptic plasticity and cognitive function. We focused on two key plasticity, learning and memory proteins: calcineurin (CaN), a CNS-abundant Ca^{2+} /Calmodulin-dependent phosphatase (Mansuy,

Winder et al. 1998; Mansuy 2003), and cAMP response element binding protein (CREB), a transcription factor indirectly regulated by CaN (Bito, Deisseroth et al. 1996; Pittenger and Kandel 1998; Silva, Kogan et al. 1998; Kinney, Sanchez-Alavez et al. 2009).

Results

The Ca²⁺/calmodulin-dependent phosphatase calcineurin (CaN) is a key negative modulator of synaptic plasticity and memory function (Mansuy 2003; Lee, Jee et al. 2004). We have previously reported that CaN hyperactivation mediates some of the detrimental effects that oligomers of amyloid-beta (A β) exert on synapses and cognition in Alzheimer's disease models (Dineley, Hogan et al. 2007; Reese, Zhang et al. 2008; Dineley, Kaye et al. 2010). These neurotoxic aggregate species share structural and functional similarities with α Syn oligomers (Glabe and Kaye 2006). As such, we chose to examine whether specific aggregates of α Syn also induce the activity of the phosphatase CaN and subsequent detrimental effects on synaptic and cognitive function through inactivation of CREB. We employed monomeric, oligomeric, and fibrillar conformations of α Syn prepared as previously described (Kaye, Head et al. 2003).

Consistent with previous reports on other oligomeric amyloid proteins (Demuro, Mina et al. 2005), treatment of human neuroblastoma SY5Y cells with oligomeric α Syn induced an increase in intracellular Ca²⁺ levels (Fig. 3.1); monomeric and fibrillar α Syn, even though added to the very same cells that were responsive to oligomeric α Syn, were ineffective.

Increased intracellular Ca²⁺ may result in activation of the Ca²⁺/calmodulin-dependent CaN. Therefore, we next determined phosphatase activity and cell survival in SY5Y cells, organotypic brain slices, and C57 wildtype mice treated with monomeric, oligomeric, and fibrillar α Syn (Figs. 3.2a, 3.2b, and 3.2c). We observed that only oligomeric α Syn increased the activity of CaN. Moreover, in the wildtype mice the

hippocampus (HIPP), amygdala (AMYG), medial cortex (MCTX), anterior cortex (ACTX), basal forebrain/septum (BFA), and cerebellum (CB) were assessed for CaN activity on freshly homogenized tissue (Fig. 3.2c). We found that CaN activity was significantly elevated in HIPP, AMYG, MCTX, and BFA of mice subjected to icv injection of α Syn compared to saline-treated mice. FK506 restored CaN activity to control levels in these brain areas of α Syn-treated mice.

One of the proteins dephosphorylated either directly or indirectly by CaN is CREB. Dephosphorylation of CREB deactivates this transcription factor that normally transcribes proteins involved with synaptic plasticity, learning, and memory (Josselyn, Kida et al. 2004; Hotte, Thuault et al. 2007). In order to ascertain if these events may be triggered by α Syn oligomers, we first sought to determine if the oligomeric and fibrillar forms of α Syn had any effect on the activity of CREB (Fig 3.3). SY5Y cells were transiently transfected with a cDNA construct encoding a secreted alkaline phosphatase (SEAP) reporter gene driven by a CREB-sensitive promoter (pCRE-SEAP).

All cells were additionally transfected with a vector encoding renilla luciferase to ensure equal transfection efficiency among samples (data not shown). Twenty-four hours after transfection, cells were treated with 2 μ M of either oligomeric or fibrillar α Syn, in the presence or absence of the adenylate cyclase (AC) activator forskolin (10 μ M). The amount of SEAP in the culture medium, assayed three hrs after treatment – a time point well before the observance of any cell death, is indicative of CREB-driven transcription. Under basal conditions, release of SEAP was not significantly diminished by treatment with oligomeric α Syn although a trend was apparent.

Cells treated with fibrillar α Syn exhibited no such reduction in SEAP. Since the level of CREB driven transcription in SY5Y cells is quite low under basal conditions, we performed a second experiment using cells treated with forskolin. This drug greatly induced PKA-promoted CREB transcription activity, evidenced by the increased SEAP

release (Fig. 3.3 right). Under these conditions, treatment of the stimulated cells with oligomeric α Syn significantly opposed the release of SEAP; those treated with fibrillar α Syn were not affected.

Next, we expanded on the initial findings from SY5Y cells showing decreased CREB-induced transcription to *ex vivo* rat brain slices and wildtype mice to investigate pCREB levels after treatment with α Syn oligomers. Figure 3.4a shows an α Syn time course experiment performed in acutely cultured rat brain slices to assess pCREB by Western blot. pCREB was maximally decreased in total protein extracts from brain slices treated with oligomeric α Syn for 15 minutes; pCREB recovered by the 30 to 60 minute time points. Conversely, monomeric and fibrillar α Syn did not affect the phosphorylation of CREB. In fact, treatment with monomer appeared to have the opposite effect (although it did not reach statistical significance). The effect on pCREB by oligomeric α Syn closely mirrored the dramatic rise in CaN activity seen in Fig. 3.2 which also peaked at 15 minutes and remained significantly increased up to 60 minutes (Fig. 3.4a). Immunohistochemical examination of the hippocampus of mice injected icv with either saline or α Syn oligomers (Fig. 3.4b) confirmed that neuronal pCREB was significantly decreased by α Syn oligomers. As well, expression of total CREB remained unchanged after icv injection of α Syn oligomers, although a trend toward reduced expression was noticeable.

FIGURES






Figure 3.1 α Syn oligomers, but not monomers or fibrils, increases intracellular Ca^{2+} levels in SY5Y cells. Graph showing a 35-minute time course of Ca^{2+} dependent fluorescence recorded and averaged from 20 fluo-3 loaded SY5Y human neuroblastoma cells in response to consecutive application of α Syn monomers, fibrils, and oligomers ($4\mu\text{M}$ for 10 min each). Cells were challenged with ionomycin ($4\mu\text{M}$) at the conclusion of the experiment. Each point represents the average of the 340/380 nm readings from 20 individual cells. Representative images on top depict the response of 4 individual cells at the time points indicated by the corresponding number on graph. Warmer colors correspond to a higher level of fluorescence.

A. Calcineurin activity in SY5Y cells



B. Calcineurin activity in rat brain slices



C. Calcineurin activity in C57 mice after α Syn oligomer icv injection




Figure 3.2 Selective induction of CaN activity and CaN-dependent cell death by oligomeric α Syn in SY5Y cells.

A. CaN (top) and combined PP1+PP2A (bottom) activity in human SY5Y neuroblastoma cells treated for 24 hr with 2 μ M α Syn monomers, oligomers or fibrils. Graph is representative of two independent experiments returning similar results. N=3 independent measurements per condition; *: $p < 0.05$ vs. control group (ANOVA).

B. Calcineurin (top) and d PP1+PP2A combined activity (bottom) assayed in the same brain slices shown in A at the end of the LTP recording. Columns represents means \pm S.D.; N=3 per group; *: $p < 0.05$ vs. control (ANOVA).

C. Calcineurin (top) and PP1+PP2A combined activity (bottom) in the hippocampus (HIPP), amygdala (AMYG), medial cortex (MCTX), anterior cortex (ACTX), basal

forebrain area (BFA) and cerebellum (CB) of the same mice sacrificed at the end of the FC memory tests.






Figure 3.3 CREB-promoted transcriptional activity is inhibited by oligomeric α Syn in both basal and AC/PKA-stimulated conditions in SY5Y cells. Release of the reported gene product SEAP in SY5Y cells transiently transfected with the CREB-sensitive CRE-SEAP construct and treated for 3 hr with oligomeric or fibrillary α Syn (2 μ M) in the presence or absence of the AC/PKA activator forskolin (10 μ M). N=6 replicates per group; *: $p < 0.01$ vs. control cells (ANOVA).

A






Figure 3.4 Oligomeric αSyn reduces pCREB levels in organotypic rat brain slices and wildtype mice after treatment with αSyn oligomers.

A. Representative Western blot (top) detecting pCREB in total protein extracts from organotypic brain slices treated with 0.75 μM of monomeric, oligomeric and fibrillar αSyn for the time length shown. The blot was stripped and re-probed for total CREB to control for sample gel loading. Densitometry band quantification (bottom) confirmed that pCREB levels were significantly reduced by αSyn oligomers but not monomers or fibrils. Graph

represent average from 3 independent experiments. *: $p < 0.05$ vs. time 0 control (ANOVA).

B. Representative confocal images illustrating pCREB expression (in red) in the granule layer of the dentate gyrus in the hippocampus of mice injected icv with vehicle or α Syn oligomers (100 nmoles/3 ml/mouse) 24 hr earlier. Time lapse between icv injection and sacrifice corresponded to the time lapse between icv injection and FC training as illustrated in (A). Sections were further co-stained for total CREB (in green) and mounted using a DAPI-containing mounting medium to visualize cell nuclei (in blue). The bar graph at the bottom illustrates the results from the image analysis of captured confocal images of sections co-stained for pCREB and CREB. $N=3$ each vehicle- or α Syn oligomer-injected mice; *: $p < 0.01$ vs. control (ANOVA).

Discussion

Taken together, our results indicate that small oligomeric aggregates of α Syn applied extracellularly to *in vitro*, *ex vivo* and *in vivo* experimental models exert profound effects on neuronal signaling involved with synaptic plasticity and memory deficits. Across the board, we found these effects to be specifically attributable to α Syn oligomeric preparations rather than monomeric or fibrillar concoctions. A model emerges whereby extracellularly applied oligomeric α Syn induces increased intracellular Ca^{2+} , CaN activation, and the dephosphorylation of a key signal transduction molecule required for synaptic plasticity, learning and memory. It is therefore prudent to propose that extracellular α Syn oligomers, through a role compromising signal transduction mechanisms that underlie synaptic function, may play a role in cognitive decline that accompanies certain synucleopathies such as PD and DLB (Schulz-Schaeffer 2010).

We found that treatment of human neuroblastoma SY5Y cells with α Syn oligomers, but not with α Syn monomers or fibrils, quickly elicited an elevation of free intracellular Ca^{2+} . Along with increased intracellular Ca^{2+} , α Syn oligomers caused an increase in the activation of the Ca^{2+} /calmodulin-responsive phosphatase CaN. This increase in CaN activation was also seen on organotypic brain slices and wildtype mice after treatment with α Syn oligomers, demonstrating the same phenomenon of α Syn oligomer-induced hyperactivation of CaN *in vitro*, *ex vivo*, and *in vivo*.

Treatment of SY5Y cells with α Syn oligomers also led to a decrease in CREB-driven transcriptional activity under both basal and forskolin-stimulated conditions; whereas fibrillar α Syn was ineffective. We also observed decreased levels of Ser133 phosphorylated CREB in organotypic brain slices and wildtype mice (without any change in total) that indicate that the transcriptionally competent form of CREB (Bito, Deisseroth et al. 1996) is diminished after treating brain slices with α Syn oligomers or injecting them icv in mice. Decreased pCREB levels were associated with increased CaN activity in brain slices and mice icv-treated with α Syn oligomers. These results suggest that α Syn oligomer-induced activation of CaN results in pCREB dephosphorylation.

As such, we propose that at least one functional outcome of extracellular α Syn oligomers on neuronal networks (e.g., hippocampus) is CaN-dependent deficits in synaptic plasticity and cognitive function. Past LTP studies from Neugebauer's lab show that expression of hippocampal LTP in brain slices is opposed by treatment with α Syn oligomers but not monomers or fibrils. This effect is accompanied by increased CaN activity and decreased CREB phosphorylation (Ser133) and can be reversed by pharmacological inhibition of CaN with FK506, suggesting that CaN is central to this α Syn-mediated impairment of synaptic plasticity. As previously noted, the crucial role of proper CaN activity and pCREB levels in LTP expression has been well established, and

there is ample consensus that LTP constitutes the cellular basis of hippocampus-dependent memory formation.

Indeed, when we injected mice icv with α Syn oligomers, we observed an increase in CaN activity and a decrease in pCREB levels in several CNS brain regions, including hippocampus. Fear conditioning studies done in Dineley's lab showed icv injection of α Syn oligomers was accompanied by a significant contextual fear conditioning impairment in this hippocampus-dependent memory task. Such α Syn oligomer-induced memory deficit was completely abolished by treatment of the mice with FK506, which also returned CNS CaN activity and pCREB levels to normal values. It is important to note that in both LTP and behavior experiments, FK506 was applied minutes to hours after α Syn oligomers, respectively, indicating that the impairments in LTP or memory elicited by α Syn oligomers under these experimental conditions are reversible and further suggests that these effects of α Syn oligomers are not the result of α Syn-induced cell death.

Indeed, we detected no change in the level of phosphorylated BAD assayed in brain tissue samples from the same animals receiving icv injection of α Syn oligomers and behavioral analysis (data not shown). Although CaN-mediated dephosphorylation/activation of the pro-apoptotic protein BAD has been described as a central event in neuronal apoptosis induced by a variety of toxic stimuli, including increased intracellular Ca^{2+} levels (Wang, Pathan et al. 1999; Springer, Azbill et al. 2000; Shou, Li et al. 2004; Yang, Omori et al. 2004), unchanged levels of BAD dephosphorylation in the brain of mice icv-injected with α Syn oligomers indicates that the observed memory deficit does not appear to involve overt neuronal death.

The presence of extracellular misfolded α Syn oligomers in neurodegenerative disorders has recently gained much attention because of its potential, albeit yet unclear role in disease progression (Lee 2008; Schulz-Schaeffer 2010). Recent investigations

have implicated that α Syn oligomers are released via an atypical secretory pathway. For example, α Syn oligomers are released in the culture medium of cells overexpressing human α Syn (Emmanouilidou, Melachroinou et al. 2010) and α Syn oligomers have been found in the spinal fluid and plasma of PD patients (El-Agnaf, Salem et al. 2003; El-Agnaf, Salem et al. 2006). Like all neurodegenerative diseases, PD has a typical neuroanatomical progression that affects the brainstem forward to the frontal cortex (Braak, Del Tredici et al. 2003), thus suggesting a prion-like mechanism of inter-cellular transmission of misfolded α Syn species (Angot, Steiner et al. 2010; Brundin, Melki et al. 2010). Indeed, neuron-to-neuron and neuron-to-astroglia transmission of misfolded α Syn species has been demonstrated *in vitro* and *in vivo* (Desplats, Lee et al. 2009; Lee, Suk et al. 2010). Furthermore, α Syn pathology deriving from the host α Syn pool has been found in fetal tissue grafted into the CNS of PD patients (Li, Englund et al. 2008; Chu and Kordower 2009) as well as in dopaminergic neurons grafted in the CNS of α Syn transgenic mice (Hansen, Angot et al. 2011). This collectively implies that aggregated α Syn species may gain access to the extracellular space where they contact and are taken up by neighboring neurons. This mechanism may be of particular significance at the synapse, where α Syn oligomers can be released presynaptically and may impact post-synaptic elements. Indeed, abundant α Syn aggregates are found at presynaptic terminals in PD and DLB (Schulz-Schaeffer 2010) and their pathological presence was associated with loss of pre- and post-synaptic markers (Kramer and Schulz-Schaeffer 2007) as well as retraction of dendritic spines in affected areas (Zaja-Milatovic, Milatovic et al. 2005; Zaja-Milatovic, Keene et al. 2006; Revuelta, Rosso et al. 2008). This neuroanatomical evidence suggests a significant loss of synapses occurring in the brains of PD and DLB patients that may underscore the cognitive symptoms of these diseases; it also introduces a neuron loss-of-function component to the pathology of

diseases like PD whose overall clinical manifestations have classically been ascribed to overt neuronal death in specific brain regions.

Therefore, our current results reveal a previously undocumented mechanism whereby small oligomeric α Syn species that have gained extracellular localization may impact healthy neurons and disturb synaptic plasticity, thus impacting memory function and cognitive ability. Our results further suggest that such pathological mechanisms may be effectively targeted by pharmacological inhibition of CaN and possibly by future immunotherapies aimed at scavenging extracellular oligomeric α Syn.

Chapter 4: Soluble alpha synuclein oligomers are associated with reduced pCREB and increased calcineurin in frontal cortex from patients with dementia with Lewy bodies

Abstract

Dementia with Lewy Bodies (DLB) is a neurodegenerative disorder that, similar to Parkinson disease, is characterized by the misfolding, aggregation and deposition of the protein alpha synuclein (α Syn). Recent evidence indicates that rather than the larger fibrils found in Lewy body deposits, the most toxic α Syn species in the aggregation pathway are the intermediate oligomeric species. However, the mechanism of action of α Syn oligomers remains elusive. Our previous studies have shown that proteins involved in synaptic welfare and memory function such as the protein phosphatase calcineurin (CaN) and pCREB (a transcription factor negatively regulated by CaN and important for synaptic integrity and memory) mediate neurotoxicity of α Syn oligomers *in vitro*, *ex vivo*, and *in vivo* and results in deficits in synaptic plasticity and memory function. On this

basis, I tested *the hypothesis that similar effects on synaptic signaling can be observed in human brains from DLB patients associated with specific α Syn oligomeric species*. Here I report that in the brains of DLB patients there is an increase in truncated CaN, a significant reduction of active pCREB, and this is associated with the appearance of α Syn dimers. Overall our results support the idea that increased CaN activity (as reflected here by CaN truncation and perturbed levels of the downstream target pCREB) mediates some of the neuro-dysfunctional effects of aggregated α Syn in humans and may thus constitute a viable pharmacological target.

Introduction

Dementia with Lewy Bodies (DLB), similar to Parkinson Disease (PD), is a debilitating and progressive neurodegenerative disease pathologically marked by the misfolding, aggregation and accumulation of the toxic protein alpha-synuclein (α Syn). α Syn is a naturally unfolded 14kDa protein primarily located at the pre-synapse of neurons and in glia (Maroteaux, Campanelli et al. 1988). Even though α Syn's normal function remains unclear, studies suggest it to be involved in regulation of vesicle trafficking (Jenco, Rawlingson et al. 1998). However, inactivation of the α Syn gene using homologous recombination does not lead to neurological dysfunction, suggesting that α Syn loss-of-function most likely does not play a role in neurodegeneration (Abeliovich, Schmitz et al. 2000). Rather, a gain-of-function of the toxic misfolding and aggregation of α Syn is a more likely etiological component in disease phenotype. Further support of α Syn as the correlate in synucleinopathies have been the discoveries of three missense mutations (A53T, A30P, and E46K) in the α Syn protein that are linked to rare forms of familial PD (Polymeropoulos, Lavedan et al. 1997; Kruger, Kuhn et al. 1998; Zarranz,

Alegre et al. 2004). Moreover, α Syn is the primary protein component of the lesions (Lewy Bodies) in brains of patients with the more common, sporadic PD. However, recent evidence has revealed that the higher molecular weight fibril aggregates found in Lewy Bodies might actually be protective by sequestering the toxic oligomeric intermediates (Olanow, Perl et al. 2004). This complements other studies showing α Syn oligomers are the most toxic species in the aggregation pathway both *in vitro* and *in vivo* (Sharon, Bar-Joseph et al. 2003; Demuro, Mina et al. 2005).

α Syn oligomers are heterogeneous (dimer, trimer, etc.) and are similar in structure to other oligomers formed by amyloid proteins whose presence characterizes other neurodegenerative diseases as demonstrated using conformational antibodies, electron microscopy and atomic force microscopy (Kayed, Head et al. 2003; Kayed, Sokolov et al. 2004; Demuro, Mina et al. 2005). One oligomeric intermediate in the amyloidogenic pathway is represented by protofibrils, which form pore-like structures that can readily integrate into the cell membrane from either intracellular or extracellular sides, thus perturbing membrane stability and consequently increasing intracellular Ca^{2+} levels (Kayed, Head et al. 2003; Demuro, Mina et al. 2005; Glabe and Kayed 2006).

While α Syn is most abundant intracellularly at pre-synaptic terminals, growing evidence suggests that it can also gain access to the extracellular space where α Syn may affect neighboring cells. Evidence that α Syn can bypass cell membranes is provided by the observation of the presence of α Syn in the CSF and plasma of PD patients (Borghini, Marchese et al. 2000; El-Agnaf, Salem et al. 2003) as well as studies showing that α Syn overexpressing neurons release α Syn in the culture medium (Lee, Patel et al. 2005). Recent studies have also shown that fetal tissue grafted into the CNS of PD patients eventually develops α Syn aggregates and Lewy bodies (Kordower, Chu et al. 2008; Li, Englund et al. 2008), suggesting the possibility of inter-neuronal

transmission of extracellular α Syn aggregates (Brundin, Li et al. 2008). Indeed, neuron-to-neuron and neuron-to-astroglia transfer of α Syn species has been reported (Desplats, Lee et al. 2009; Lee, Suk et al. 2010), and α Syn pathology can spread from the host to fetal tissue grafted into the CNS of PD patients (Li, Englund et al. 2008; Chu and Kordower 2009) or to dopaminergic neurons grafted in the CNS of α Syn transgenic mice (Hansen, Angot et al. 2011).

Oligomer-induced rises in intracellular Ca^{2+} profoundly affect neuronal function and eventually cause neuronal death (Volles and Lansbury 2003); consequently, any neuron type exposed to intracellular or extracellular aggregating α Syn (Braak, Del Tredici et al. 2003) can be dysfunctionally affected through permeabilization of the cell membrane, which may be one common event underlying synucleinopathy pathology, and thus represent a target for therapeutic intervention; however, the downstream mechanisms linked to oligomeric α Syn induced neurotoxicity are still poorly understood. Research conducted in our laboratory in the recent past has focused on effects of amyloid oligomers on Ca^{2+} homeostatic regulation and its consequences on the activity of calcineurin (CaN, a Ca^{2+} -sensitive protein phosphatase abundant in the brain and involved in synaptic plasticity and memory function) and concomitant dephosphorylation and deactivation of cAMP response element binding (CREB, a transcription factor involved in synaptic plasticity, learning, and memory). Recently, we have shown that synthetic oligomeric α Syn causes an increase in intracellular Ca^{2+} , CaN activation, and decrease in pCREB *in vitro*, *ex vivo*, and *in vivo* (Neugebauer et al., *this issue*), thus perturbing events that are known to modulate synaptic plasticity and cognition. Indeed, I further showed that α Syn oligomers induce cell death, oppose LTP expression, and impair memory in a CaN-dependent fashion. The present study extends those findings to the actual diseased human brain, demonstrating increased α Syn oligomeric species that

occur concomitant to increased active CaN and decreased pCREB levels in postmortem brain samples from a cohort of DLB patients as compared to age-matched control.

Results

I first examined the presence of α Syn oligomeric species, CaN activity, and pCREB levels in the frontal cortices from DLB patients and age-matched controls. Diagnosis, age, sex, and PMI of the cohort of individuals who donated the cortices employed in this study are shown in Table 4.I. Immunohistochemical analysis revealed the presence of α Syn aggregates in frontal cortices of DLB brains that were not seen in age-matched controls (Fig. 4.1), and western blot analysis demonstrated monomers along with detectable levels of α Syn oligomers (dimers to hexamers, according to the apparent molecular weight) in both DLB and age-matched control samples (Fig. 4.2). Notably, the dimer was increased in the DLB as compared to control cortices while levels of α Syn monomer, trimer, and hexamer did not differ between DLB and control samples. In order to determine the stability of these amyloid aggregates, the human samples were also treated with either urea, which is known to disassemble aggregates through hydrogen bonding interactions, or proteinase K, which is known to digest proteins particularly at aromatic and aliphatic residues. Western blot analysis using a polyclonal anti- α Syn antibody demonstrated high sensitivity to proteinase K both in control and DLB samples and partial sensitivity to urea. The control sample demonstrated a greater sensitivity to urea than DLB while the higher molecular weight hexamers in both control and DLB samples demonstrated greater resistance to urea (Supplementary Fig. 4.1). These results are consistent with a report of α Syn sensitivity to proteinase K and resistance to urea in a Tg A53T mouse model (Tsika, Moysidou et al.).

As suggested in this publication using Tg A53T mice, the urea-resistant bonds seen in the human samples could possibly be caused by posttranslational modifications.

Next, in order to determine activation of CaN in these same samples I measured levels of the 57 KDa, truncated form of subunit A of CaN. Levels of truncated CaN-A reflect levels of the active enzyme in that upon activation of CaN, concurrent truncation of the subunit A occurs to reveal the active site of the enzyme (Liu, Grundke-Iqbal et al. 2005). This indirect approach to measure levels of active CaN in autopsy tissue specimens is necessary since CaN is rapidly deactivated by post-mortem oxidation, thus making direct measurements of CaN enzymatic activity using commercially available kits highly unreliable (Wang, Culotta et al. 1996). Western blot analysis revealed that truncated CaN was increased in the DLB samples relative to age-matched control (Fig. 4.3), suggesting increased CaN activity in the DLB brains. Along with increased truncation of CaN, levels of phosphorylated CREB were dramatically reduced in the nuclear fraction from the DLB samples as compared to controls, whereas levels of total CREB were relatively unchanged between the two groups (Fig. 4.4). Immunohistochemical analysis of the human brain samples confirmed the marked reduction of pCREB in the samples from DLB patients (Fig. 4.5). Notably, double staining of the sections with NeuN, a neuronal marker, showed that such reduction affected pCREB in both neuronal (NeuN⁺) and non-neuronal (NeuN⁻) cells. It is unlikely that the observed changes in α Syn or pCREB levels in these human brains were due to differential protein degradation in samples collected at different post-mortem interval (PMI). Indeed, neither α Syn nor pCREB levels showed any significant correlation with the PMI collection times of the tissues specimens studied here (α Syn 1mer: $r^2=0.112$, $p=0.812$; 2mer: $r^2=-0.232$, $p=0.617$; 3mer: $r^2=0.001$, $p=0.999$; 6mer: $r^2=0.222$, $p=0.633$. pCREB: $r^2=-0.390$, $p=0.387$). On the other hand, when the levels of pCREB were compared to various α Syn species in individual DLB samples, I found that there was a

significant negative correlation between pCREB and the amount of the α Syn dimer, whereas there was a significant positive correlation between pCREB and the levels of α Syn monomer (Fig. 4.6). The same analysis returned no significant correlations between pCREB and α Syn species in brain samples from age-matched control individuals (1mer: $r^2=0.121$, $p=0.974$; 2mer: $r^2=0.171$, $p=0.784$; 3mer: $r^2=0.009$, $p=0.989$; 6mer: $r^2=0.580$, $p=0.306$).

FIGURES





Figure 4.1 Immunohistochemistry reveals α Syn aggregates in the DLB frontal cortex that is not seen in age-matched controls. Representative confocal images

illustrating α Syn aggregates in the cortex of a DLB patient (D) in comparison to an age-matched control (C). Sections were mounted using a DAPI-containing mounting medium to visualize cell nuclei.






Figure 4.2 Increase in dimeric α Syn oligomers. Representative Western blot (top) detecting α Syn monomer (1mer) and oligomers (2-6mer) in soluble protein extracts from the frontal cortex of DLB patients (D) and age-matched controls (C). (Bottom) Densitometric analysis of immunoreactive bands comparing levels of individual α Syn species in frontal cortices from DLB patients (N=7) and age-matched controls (N=5). *: $p < 0.05$ vs. control (ANOVA).




Figure 4.3 Truncation (activation) of CaN is increased in the DLB frontal cortex.

(Top) Representative Western blot detecting CaN subunit A in protein extracts from frontal cortex of DLB (D) and age-matched controls (C). Membrane was stripped and re-probed for β -actin (loading control). (Bottom) Densitometric analysis of immunoreactive bands comparing CaN truncated subunit A levels in frontal cortices from DLB patients (N=7) and age-matched controls (N=5). *: $p < 0.05$ vs. control (ANOVA).







Figure 4.4 Phosphorylation (activation) of CREB is decreased in the DLB frontal cortex. (Top) Representative Western blot detecting pCREB in protein extracts from the frontal cortex of DLB (D) and age-matched controls (C). Membrane was stripped and re-probed for total CREB, NeuN (neuronal marker), and β -actin (loading control). (Bottom) Densitometric analysis of immunoreactive bands comparing CREB and pCREB levels in frontal cortices from DLB (N=7) and age-matched controls (N=5). *: $p < 0.001$ vs. control (ANOVA).






Figure 4.5 Immunohistochemistry confirms a reduction of pCREB in the DLB frontal cortex that affects both neuronal and non neuronal cells. Representative confocal images illustrating pCREB expression in the cortex of a DLB patient in comparison to an age-matched control. Sections were further co-stained for total CREB (upper two rows) or NeuN (a neuronal marker, bottom two rows) and mounted using a DAPI-containing mounting medium to visualize cell nuclei. Both neuronal (NeuN⁺, solid-head arrows) and non neuronal (NeuN⁻, open-head arrows) cells expressed detectable pCREB that was appreciably reduced in DLB for both cell types. The bar graph at the bottom illustrates the results from the image analysis of captured confocal images of

sections co-stained for pCREB and CREB. N=4 each DLB and control; *: $p < 0.01$ vs. control (ANOVA).




Figure 4.6 Levels of α Syn dimers are inversely correlated with levels of pCREB in the DLB frontal cortex. Correlation analysis comparing levels of monomer, dimer, trimer and hexamer species of α Syn to levels of pCREB (adjusted for CREB levels in the same sample) in the DLB frontal cortex. Levels for both α Syn species and pCREB/CREB ratio were expressed as fraction of the average of the corresponding value in age-matched controls, which was thus set equal to 1.

Discussion

These results provide evidence that there are mechanisms linking α Syn aggregates and signaling elements important for synaptic plasticity that may be at play in actual brains from humans affected by clinically diagnosed DLB. Specifically, in these

human DLB brains I found significantly higher levels of α Syn dimer (Fig. 4.2), higher levels of truncated, active CaN (Fig. 4.3), and lower levels of pCREB (Figs. 4.4 and 4.5). In addition, I found that levels of the α Syn dimer had a significant negative correlation with pCREB levels (Fig. 4.6). It is therefore prudent to hypothesize that α Syn oligomers, through affecting levels of elements such as CaN and pCREB that are intimately involved in the control of synaptic plasticity, may play a role in cognitive decline accompanying the progression of DLB, and possibly other synucleinopathies.

I could not directly measure CaN activity in the brain samples used in the present studies as its enzymatic activity, regardless of disease state, was extremely low and often indistinguishable from background values (not shown). Loss of phosphatase activity, and particularly CaN, is common in autopsy specimens where quick post-mortem oxidative deactivation of phosphatases cannot be practically prevented through timely cryopreservation (Wang, Culotta et al. 1996). However, based on past literature showing a selective and typical truncation of the subunit A upon CaN activation (Liu, Grundke-Iqbal et al. 2005), I was able to measure levels of truncated CaN as an indicator of CaN activation and found a significant increase in DLB tissue relative to control (Fig. 4.3). This finding is notable because it is known that activation of CaN is both Ca^{2+} and calmodulin dependent (Mansuy 2003), which corresponds with our earlier findings that synthetic oligomeric α Syn causes an increase in intracellular Ca^{2+} and CaN activation. Moreover, I observed a dramatic decrease in CREB phosphorylation in human cortex samples from patients affected by DLB as compared to age-matched controls (Figs 4.4 and 4.5). Such a decrease was correlated with increased levels of a specific α Syn dimeric oligomer (Fig. 4.6), suggesting that a similar mechanism linking oligomeric species of α Syn and decreased pCREB as previously observed in experimental models (Neugebauer et al., this issue) may be at play in the actual diseased human brain. Moreover, it is particularly notable that the dimeric species was

the only oligomeric species significantly higher in DLB brains relative to control (Fig. 4.2) and had the highest negative correlation with pCREB levels (Fig. 4.6) in that growing literature evidence pertaining to the Alzheimer's amyloid-beta peptide points to the dimers as being the most synaptic toxic oligomers of this particular amyloid protein (Jin, Shepardson et al. ; Shankar, Li et al. 2008; Mc Donald, Savva et al. 2010). With this in mind, even though I detected α Syn oligomers in brain specimens from age-matched control subjects (Fig. 4.2), no α Syn oligomeric species was statistically correlated to pCREB levels in the healthy human cortices (data not shown), suggesting that an additional factor, likely specific to the disease state, is necessary to render α Syn oligomers (particularly dimers) capable of affecting pCREB levels. What this putative factor may be is currently unknown; even though it is extremely tempting to speculate that a mechanism involving α Syn oligomers causing Ca^{2+} dyshomeostasis may be an attractive possibility that however awaits experimental confirmation.

Ca^{2+} dyshomeostasis leading to synaptic dysfunction has been shown to be one common event observed in neurodegenerative diseases (Mattson 2007); however the concurrent signaling events such as phosphatase or kinase level modulation has not been fully elucidated. Studies have shown opposing effects from amyloid aggregates on phosphorylation events (Price, Rockenstein et al. ; Yuan, Sun et al. ; Hashimoto and Masliah 2003; Reese, Zhang et al. 2008). This possibly could be explained by different experimental models or brain areas studied. However due to the predominant location of α Syn in the presynapse and its role in vesicle trafficking, it seems likely that pathological effects elicited by abnormally aggregated α Syn would lead to synaptic dysfunction. Our study points to one possible molecular mechanism through which the oligomeric species of α Syn affect these synaptic systems through its effects on CaN activation and decreased levels of pCREB. This is complemented by studies showing upregulation of CaN in aged brains and its correlation to the degree of cognitive impairments (Foster,

Sharrow et al. 2001; Foster 2007). Since DLB is a cognitive disorder, it is therefore tempting to speculate a direct correlation between α Syn oligomers and CaN hyperactivation in the pathology of DLB.

In conclusion, our findings illustrate molecular events that could mediate the impact of α Syn oligomers on synaptic dysfunction in the DLB human cortex, namely activation of CaN and associated dephosphorylation of CREB. Since these events precede overt cell death, it is conceivable that synaptic dysfunction can be reversible and thus amenable to pharmacological intervention. It is therefore prudent to suggest that CaN inhibition should be considered as a possible therapeutic strategy for DLB and other synucleinopathies.

Chapter 5: Seeding of alpha synuclein aggregation by nitrated alpha synuclein promotes the formation of stable oligomers with increased toxicity.

Abstract

Synucleinopathies such as Parkinson disease make up a group of neurodegenerative disorders characterized by Lewy Bodies which are insoluble protein aggregates formed through β -sheet interactions containing predominantly fibrils of α Syn protein. Soluble oligomeric intermediates of the fibrillation pathway have shown to be the most toxic species. One mechanism of toxicity of α Syn oligomers is through membrane destabilization which results in increased intracellular Ca^{2+} and altered cell signaling homeostasis as described in the previous chapters.

Oxidative and nitrative stressors have also been shown to be associated with synucleinopathies, but the exact mechanism of toxicity is not well understood. α Syn oligomers formed in response to nitration associate through covalent dityrosine

crosslinking, unlike the non β -sheet interaction that marks amyloid aggregates, thus suggesting the existence of substantial differences between oligomers formed by nitrated α Syn as compared to unmodified α Syn. The present study was therefore aimed at investigating structural and functional differences between oligomeric aggregates obtained from nitrated and non-nitrated α Syn. The results show that nitrated α Syn demonstrates conformational differences both on Western blot and AFM along with increased resistance to β -sheet disrupters. Unlike unmodified α Syn oligomers, nitrated α Syn oligomers have no impact on intracellular Ca^{2+} in SY5Y human neuroblastoma or on early expression of LTP and pCREB in rodent brain slices. However, decreased cell viability was observed in SY5Y cells after treatment with nitrated α Syn species for twenty-four hours. Notably, α Syn seeded with nitrated monomers (1:10) causes substantially greater toxicity than unseeded α Syn oligomers, which suggests that detrimental effects of nitrated α Syn in synucleinopathies may be exerted indirectly. Indeed, the present study suggests one causal mechanism for synuclein pathology being nitrative stress-related α Syn modifications initiating potent amyloid toxicity of otherwise normal α Syn.

Introduction

Synucleinopathies are a group of neurodegenerative disorders characterized by Lewy Bodies which are insoluble aggregates containing predominantly α Syn protein (Baba, Nakajo et al. 1998). All known synucleinopathies share a similar mechanism of neuropathology that involves a native monomeric α Syn protein structure rearranging to a β -sheet rich conformation followed by nucleation-dependent aggregation into soluble oligomers, protofibrils, fibrils, and finally Lewy body deposits (Jarrett and Lansbury 1993; Harper and Lansbury 1997; Makin and Serpell 2002). Within these different α Syn aggregated species, the oligomer and protofibril intermediates have shown to be the

most toxic (Sharon, Bar-Joseph et al. 2003; Olanow, Perl et al. 2004; Demuro, Mina et al. 2005).

Annular protofibrils can readily integrate into the cell membrane, perturbing membrane permeability, and creating ion dyshomeostasis such as increased intracellular Ca^{2+} levels (Ding, Lee et al. 2002; Lashuel, Hartley et al. 2002; Lashuel, Petre et al. 2002; Kaye, Head et al. 2003; Zhu, Li et al. 2003; Demuro, Mina et al. 2005; Glabe and Kaye 2006). Evidence to show αSyn 's ability to bypass cell membranes is shown by αSyn 's presence in the CSF and plasma of PD patients (Borghi, Marchese et al. 2000; El-Agnaf, Salem et al. 2003), studies showing cultured neurons releasing αSyn in the medium (Lee, Patel et al. 2005), and fetal tissue grafted into the CNS of PD patients eventually developing αSyn aggregates (Kordower, Chu et al. 2008; Li, Englund et al. 2008). Other indications of protofibril toxicity is demonstrated in three missense mutations (A53T, A30P, and E46K) in the αSyn protein that are linked to rare forms of familial synucleinopathy PD and that form predominantly protofibril structures while having a significantly greater membrane destabilizing effects, suggesting this mechanism of toxicity by αSyn protofibrils as being a key event in PD pathology (Conway, Harper et al. 2000; Lashuel, Hartley et al. 2002; Lashuel, Petre et al. 2002; Volles and Lansbury 2002).

Oligomer-induced ion dyshomeostasis such as rises in intracellular Ca^{2+} could profoundly affect neuronal function and eventually cause neuronal death through mechanisms such as hyperactivation of the phosphatase calcineurin (CaN, a critical regulator of Ca^{2+} signaling, synaptic plasticity, learning and memory, and cell survival) (Winder, Mansuy et al. 1998; White, Sullivan et al. 2000; Josselyn, Kida et al. 2004; Yang, Omori et al. 2004), causing CREB dephosphorylation (Winder, Mansuy et al. 1998; Nishi, Snyder et al. 1999; Josselyn, Kida et al. 2004). Dephosphorylation and

inactivation of this transcription factor causes a decrease in synaptic plasticity, long-term potentiation (LTP, the cellular basis of learning and memory), and learning and memory (Mansuy, Mayford et al. 1998; Schulz, Siemer et al. 1999; Malleret, Haditsch et al. 2001).

However, some α Syn oligomeric species, such as those formed in a nitrative or oxidative environment, are derived from an off-pathway aggregation and may thus differ both structurally and functionally from oligomers formed by unmodified α Syn. Nitrative conditions cause covalent dityrosine crosslinking that bypasses the nucleation-dependent lag phase, thus leading to a much quicker formation of oligomers (Zhou, Long et al. ; Yamin, Uversky et al. 2003) that have increased stability (Souza, Giasson et al. 2000; Norris, Giasson et al. 2003; Uversky, Yamin et al. 2005), and reduced propensity to form fibrils (Souza, Giasson et al. 2000; Yamin, Uversky et al. 2003; Uversky, Yamin et al. 2005). Importantly, dityrosine crosslinking can also occur between preformed aggregates, but because these aggregates are already in parallel, register conformation, their structure differs from that of aggregates formed through dityrosine crosslinking between monomers in that these latter do not involve β -sheet-driven interactions and consequently in-register conformation (Souza, Giasson et al. 2000; Norris, Giasson et al. 2003; Ruf, Lutz et al. 2008).

Evidence has revealed an association between nitrative/oxidative stress and synucleinopathies. For instance, nitrative stress and synucleinopathy incidences increase with age and both elicit insult on the post-mitotic neurons (Choi, Zhang et al.). Furthermore, it is thought that dopaminergic neurons are most susceptible during PD because of the oxidative environment created through dopamine metabolism (Dauer and Przedborski 2003). More directly, oxidative and nitration stress have also been observed

on Lewy body deposits in postmortem PD and DLB brains (Duda, Giasson et al. 2000; Giasson, Duda et al. 2000; Gomez-Tortosa, Gonzalo et al. 2002; Dalfo, Portero-Otin et al. 2005). Other studies have shown nitrate stress being the mediator between the synergism of environmental stimuli (such as inflammatory-stimulating agents or herbicides) and Tg α Syn animal models (Peng, Oo et al. ; Yu, Xu et al. ; Gao, Kotzbauer et al. 2008). Another recent study has shown using an internalization signaling peptide on α Syn that nitrated α Syn is more toxic than non-nitrated α Syn (Yu, Xu et al.); however, the same authors point out that the toxicity was diminished when the internalization tag was removed, implying that the mechanism of this toxicity doesn't involve membrane instability. Indeed, even though α Syn's most commonly-known mechanism of toxicity is through membrane destabilization (Lashuel, Hartley et al. 2002; Volles and Lansbury 2003), not all α Syn oligomers share this characteristic (Uversky ; Fink 2006).

Notably, nitrated and non-nitrated α Syn can still influence each other's aggregation pathway as studies have shown that even substoichiometric amounts of the heterogeneous oligomers created through oxidative and nitrate modifications lead to fibril inhibition of non-modified α Syn (Zhou, Long et al. ; Yamin, Uversky et al. 2003; Uversky, Yamin et al. 2005). Such reported substoichiometric effects of nitrated α Syn on non-nitrated α Syn are of particular significance to the neuropathology of synucleinopathies because it has been shown that only a fraction of the total α Syn pool is nitrated during nitrate stress (Hodara, Norris et al. 2004). This suggests that even a minor fraction of the α Syn pool that is nitrated under condition of oxidative stress may have a dramatic impact on the unmodified α Syn structure and toxicity; consequently, there may exist an indirect association between protein nitrate events and neurodegeneration that implicates oxidative stress being a causative factor into synuclein-pathology. On these bases, the present study investigated toxicity of nitrated

α Syn aggregated species per se as well as the toxicity of unmodified α Syn oligomers formed through seeding with substoichiometric amounts of nitrated α Syn aggregates.

Results

Recombinant α Syn was nitrated using TNM either before or after oligomerization in order to compare nitration effects on monomer, nitration effects on pre-formed oligomer, and non-nitrated α Syn. Structural differences between the nitrated and non-nitrated species were assayed using Western blot and AFM analyses (shown in Figure 5.1). Nitrated monomer (Nmono) and α Syn oligomer were first tested on Western probed with anti- α Syn. Nmono had multiple bands even though it was not subject to the oligomerization procedure (see Methods), implying that nitration per se induces oligomerization of α Syn monomer. Also, even though both samples had multiple bands (reflecting the presence of oligomeris species), the apparent molecular weight of the bands in the Nmono sample was shifted as compared to α Syn oligomer's bands, suggesting that the two structures were different resulting in different electrophoretic migration patterns. Specifically, Nmono species migrate faster down the electrophoretic gel than unmodified α Syn oligomer, implying Nmono has a tighter, more rigid structure (Western blot shown in Figure 5.1A).

Nmono and α Syn oligomer Western blots were also probed with anti-NitroSyn. As expected, α Syn oligomer did not reveal any bands; however, Nmono had bands at the same location as the bands revealed by probing the gel with anti- α Syn, confirming proper nitration of the α Syn recombinant protein. Nmono and α Syn oligomer blots were further probed with anti-NitroTyr; as expected, α Syn oligomer did not show any immunoreactivity. On the other hand, Nmono revealed bands at the same location as observed in the previous two blots, suggesting that nitration occurred at the Tyr residues

of α Syn (Blot shown in Figure 5.1A). Western blot analysis was also done on nitrated pre-formed α Syn oligomers (Noligo) and probed with anti-NitroSynuclein to evaluate whether there were nitration differences between Nmono and Noligo; the blot revealed bands of similar apparent molecular weight, even though Nmono revealed increased higher molecular weight species than Noligo. Also, Nmono had more intense staining than Noligo, suggesting more nitration had occurred on Nmono than Noligo (Blot shown in Figure 5.1B). AFM analyses on Nmono, Noligo, and α Syn oligomer revealed structural differences as well. For instance, the α Syn oligomer image showed primarily small spherical structures, the Nmono image revealed bigger globular structures, while the Noligo image returned a mixture of both (AFM shown in Figure 5.1C).

To further investigate structural differences among the three α Syn species, chaotropic treatment with known β -sheet disrupters acetonitrile and hexa-fluoro-isopropranol (HFIP) was performed and compared to non-treated samples by Western blot probed with anti- α Syn. Nmono and Noligo did not demonstrate band differences before and after chaotropic treatment, whereas α Syn oligomers had increased monomers and decreased aggregates after chaotropic treatment. This result suggests that molecular interactions other than β -sheet (e.g., dityrosine crosslinking between individual α Syn proteins) occur in the aggregates of the nitrated species (Blot and densitometry analysis shown in Figure 5.2).

To investigate possible differences in cellular effects amongst the different α Syn species, intracellular Ca^{2+} levels were measured on fura-2-loaded SY5Y cells after treatment with 4 μM of the different α Syn species. Consistent with our previous results (Chapter 3), α Syn oligomers caused an increase in intracellular Ca^{2+} immediately after treatment (Figure 5.3A). On the other hand, treatment of Nmono did not increase intracellular Ca^{2+} (Figure 5.3B) and Noligo evoked an increase in intracellular Ca^{2+} levels

immediately after treatment, but not as robust as α Syn oligomer (Figure 5.3C). While this latter observation may indicate the presence of residual non-nitrated oligomers in the Noligo sample, collectively these experiments suggest that it is unlikely that nitrated species induce cell toxicity through increased intracellular Ca^{2+} .

Neuronal cell effects of nitrated α Syn was further investigated on LTP expression that was measured on rat brain slices that were treated with 0.5 μM of the different α Syn species. Consistent with our previous results (Chapter 3), α Syn oligomers completely abolished LTP expression. Nmono and Noligo did not abolish LTP expression at first, but its duration was shorter than that recorded in non-treated, control slices (Figure 5.4A). On these same brain slices, pCREB/CREB was measured at the end of the recording period using Western blot analysis. Also confirming our previous results, pCREB levels were decreased in the α Syn oligomer treated slices; however, pCREB levels were unchanged after Nmono or Noligo treatment, implying no effect on pCREB levels during the duration of the sixty minute recording (Figure 5.4B).

Next, I measured possible structural differences between α Syn aggregated in the presence of substoichiometric amounts (seed) with Nmono (Nseeded, 1:10) in comparison with α Syn aggregated under non-seeded conditions. Both samples were stirred five days (a time period usually resulting in abundant fibril formation) and evaluated using Western blot probed with anti- α Syn and AFM analyses. Western blot was performed using two different gel concentrations, 10% and 6% acrylamide, so as to best separate low and high molecular weight aggregates, respectively. Non-seeded α Syn had higher molecular weight bands displayed in the 6% gel and decreased lower molecular weight bands in the 10% gel, implying expected fibril formation in this sample. On the other hand, the Nseeded sample had increased oligomeric species as detected in the 10% gel and much less higher molecular weight species revealed on the 6% gel as compared to non

seeded α Syn, implying the seeding with Nmono caused inhibition of α Syn fibrillation (Figure 5.5A). AFM analysis of these two samples confirmed the Western blot results in that the non-seeded sample primarily contained fibrillar α Syn while the Nseeded sample was composed of smaller spherical species (Figure 5.6B). This is consistent with literature demonstrating that seeding α Syn with nitrated α Syn results in the formation of stable oligomers that do not further aggregate into fibrils.

Cell viability was measured on SY5Y cells twenty-four hours after treatment with 4 μ M of the α Syn species. As compared to untreated control cells, α Syn oligomer-treated cells had ~55% viability, Nmono-treated cells had ~70% viability, Noligo-treated had ~50% viability, Nseeded-treated had ~15% viability, and α Syn fibrils had ~95% viability (figure 5.6A). These results suggest that all α Syn aggregated species induced cell toxicity, with the exception of α Syn fibrils. Notably, treatment with Nseeded produced the highest degree of toxicity in the SY5Y cells. To determine the concentration of Nseeded that elicits the same level of toxicity as 4 μ M α Syn oligomers, I treated cells with increasing doses of Nseeded (ranging 0.5 to 4 μ M) and observed that the toxicity induced by Nseeded applied at 1-2 μ M was comparable to that induced by 4 μ M α Syn oligomers (indicated by a red line in Figure 5.6A,B).

Intracellular Ca^{2+} levels were measured on fura-2 loaded SY5Y cells after treatment with different concentrations of Nseeded α Syn. Measuring levels of intracellular Ca^{2+} after adding 4 μ M Nseeded was not achievable because the fura-2 dye was immediately released outside of the cells upon treatment (Figure 5.7A). Similar results were obtained after treatment with 2 μ M Nseeded (Figure 5.7B). One possibility to explain these results is that concentrations of 2 and 4 μ M Nseeded cause immediate membrane destabilization to the cells, thus leading to loss of intracellular Fura-2 dye and eventually death of cells. On the other hand, treatment of SY5Y cells with 1 μ M Nseeded

did not elicit an increase of intracellular Ca^{2+} (Figure 5.7C), implying a concentration higher than 1 μM but lower than 2 μM of Nseeded αSyn being at least equivalent to the effect elicited by 4 μM αSyn oligomers. This is consistent with the results observed in the cell viability experiments, where treatment with Nseeded resulted 2 to 4 times more toxic αSyn oligomers. LTP studies were also attempted using Nseeded treatment on rat brain slices, but no synaptic output could be measured, suggesting that treatment with Nseeded was more toxic than treatment of αSyn oligomers (data not shown). Collectively, these experiments suggest Nseeded αSyn oligomers are substantially more toxic than non-seeded αSyn oligomers.




Figure 5.1: α Syn nitrated by TNM confirmed using Western blot and AFM. Representative Western blots (A) detecting α Syn oligomers and/or Nmono using antibodies for α Syn, NitroSyn, and NitroTyr. Representative Western blots (B) detecting Nmono and Noligo using antibody for NitroSyn. AFM images (C) of α Syn oligomers, Nmono, and Noligo.




Figure 5.2: Nitrated α Syn resistant to β -sheet disrupting compounds acetonitrile and HFIP. (Top) Representative Western blot detecting α Syn oligomers, Nmono, and Noligo with and without treatment of acetonitrile and HFIP. (Bottom) Densitometric analysis of immunoreactive bands comparing treated and untreated samples. *: $p < 0.05$ treated vs. untreated of α Syn oligomers (ANOVA).




Figure 5.3: Nitrated α Syn has no effect on intracellular Ca^{2+} levels as compared to α Syn oligomers on SY5Y cells. Representative images illustrating intracellular Ca^{2+} stained with fura-2 and graphs depicting fluorescent readout of 340/380 nm after treatment with α Syn oligomers (A), Nmono (B), and Noligo (C). N=30.




Figure 5.4: Nitrated α Syn shortens duration of LTP expression but has no effect on pCREB levels after sixty minutes. Graph (A) representing percent amplitude of EPSCs after treatment with α Syn oligomers, Nmono, or Noligo. Western blot (B) measuring pCREB/CREB levels on soluble protein fraction of rat brain slices used for LTP experiment.




Figure 5.5: Seeding α Syn with N α Syn (1:10 N α Syn: α Syn) and stirred 5 days leads to different structure from α Syn stirred alone 5 days. Western blots (A) of Nseeded and α Syn after five days stirring on 6% and 10% acrylamide gels. AFM images (B) of Nseeded and α Syn after five days stirring.






Figure 5.7: 4 and 2 μM Nseeded αSyn causes release of fura-2 from cells while 1 μM Nseeded shows no increase in intracellular Ca^{2+} on SY5Y cells. Representative images illustrating intracellular Ca^{2+} stained with fura-2 and graphs depicting fluorescent readout of 340/380 nm after treatment with 4 μM Nseeded two sequential times (A), 2 μM Nseeded (B), and 1 μM Nseeded (C). N=30.




Figure 5.6: Nitrated αSyn show decreased cell viability after twenty-four hours, but Nseeded most toxic. Graphical representation (A) of cell viability using MTS after twenty-four hours treated with αSyn oligomer, Nmono, Noligo, Nseeded, or fibrils. Graphical representation (B) of cell viability using MTS of 0.5, 1, 2, or 4 μM Nseeded αSyn. N=3.

Discussion

This study provides evidence that there are structural and functional differences between nitrated αSyn and non-nitrated αSyn. Furthermore, this study demonstrates profound differences of Nseeded αSyn and non-seeded αSyn after five days stirring both structurally and functionally. Structurally, it is known that covalent modifications such as dityrosine crosslinking results in conformations different from amyloid oligomers formed through β-sheet interactions (Ruf, Lutz et al. 2008). This is also demonstrated in Figure 5.1A on the anti-αSyn Western blot illustrating bands from the Nmono sample migrate faster down the electrophoretic gel than αSyn oligomer, implying conformational changes of Nmono to a more rigid and stable structure. Also, Figure 5.1C demonstrates

structural differences amongst the α Syn species in that the α Syn oligomer image showed primarily small spherical structures, the Nmono image revealed bigger globular structures, while the Noligo image returned a mixture of both, demonstrating conformational differences of the oligomeric species that is presumably caused by covalent crosslinking in the nitrated species relative to β -sheet interactions in α Syn oligomer. It is interesting that the Western blot shown in Figure 5.1B demonstrates both greater anti-NitroSynuclein staining and higher molecular weight bands in the Nmono as compared to Noligo sample. It is conceivable that the monomer conformation of α Syn could possibly have increased Tyr availability for nitration, causing nitration-influenced acceleration of oligomerization, while the pre-formed oligomers are in a parallel, in-register stacked conformation with Tyr grouped together causing limited nitration (Ruf, Lutz et al. 2008). However, it is compelling that the Nmono and Noligo bands are at the same location on the Western blot if their conformations differ. Perhaps the covalent effects are more profound than β -sheet interactions, causing increased stability and rigidity. Indeed, it is documented that off-pathway oligomeric α Syn species have increased stability resulting from covalent interactions (Souza, Giasson et al. 2000; Yamin, Uversky et al. 2003; Uversky, Yamin et al. 2005). This is also demonstrated in Figure 5.2 where the nitrated species show increased resistance to β -sheet disrupters.

It is also known that the structural changes caused by dityrosine crosslinking can result in deleterious effects on α Syn's normal function in vesicle trafficking (Hodara, Norris et al. 2004), but not much is known about neurotoxicity as compared to unmodified α Syn oligomers. The present study shows functional differences with α Syn oligomer treatment on intracellular Ca^{2+} levels, LTP expression, and CREB phosphorylation. For example, Figure 5.3B demonstrates no increase of intracellular Ca^{2+} after treatment with Nmono, and Figure 5.3C shows only a limited increase of

intracellular Ca^{2+} after treatment with Noligo, which is in contrast with αSyn oligomer treatment that results in a significant increase of intracellular Ca^{2+} as shown in Figure 5.3A. One explanation for differences in intracellular Ca^{2+} elicited by the nitrated αSyn species is that these species have conformational differences from αSyn oligomers through covalent bonding interactions, as demonstrated in the Western blot and AFM analyses shown in Figures 5.1 and 5.2. Such covalent bonds between individual αSyn proteins would produce aggregates that do not possess structural and functional amyloid features since their interaction is not driven by the formation and anti-parallel juxtaposition of β -sheets that is the core feature of amyloid aggregates.

Nmono and Noligo did not abolish LTP expression at first, but the duration of expression was shorter than that recorded in non-treated, control slices (Figure 5.4A). One possible explanation for decreased duration of LTP expression is that the nitration efficiency of the samples could possibly not be complete, and amyloid aggregation of the non-nitrated αSyn portion in the sample could be seeded by the nitrated portion to form toxic oligomers at a lower concentration. On the other hand, the nitrated species did not affect pCREB levels sixty minutes after treatment as shown by Western blot (Figure 5.4B). Going with the idea of inter-seeding of the nitrated samples, it is probable that sixty minutes was not a sufficient time to elicit effects on CREB dephosphorylation since this event is downstream of oligomer-induced decreased LTP expression. Nonetheless, further studies should be done on brain slices using longer time periods to determine if effects on pCREB could eventually be observed. In addition, isolation of nitrated αSyn from potentially non-nitrated αSyn using affinity chromatography could be performed to ensure purity of the samples. The same phenomenon of intra-sample seeding by nitrated αSyn of toxic oligomers from residual non-nitrated αSyn could explain the cell viability data observed after twenty-four hour treatment (Figure 5.6A). The toxicity

observed in the nitrated α Syn samples at these longer time points complements the idea that incomplete nitration (leading to nontoxic nitrated α Syn aggregates but sparing residual α Syn molecules) would in time promote the formation of exceptionally toxic non-nitrated α Syn oligomers (however seeded by nitrated α Syn) that would induce toxicity even at nominal concentrations much lower than non-seeded α Syn oligomers.

To address this important point, the effects of Nseeded α Syn were evaluated using Nmono to seed α Syn at a (1:10) stoichiometric ratio. Figure 5.5 shows, using both Western blot and AFM analyses, that seeding α Syn with Nmono results in oligomeric species that did not further aggregate to form fibrils. These results confirm prior studies revealing that fibrillation of nitrated α Syn-seeded α Syn is inhibited and stable oligomers are primarily formed (Yamin, Uversky et al. 2003). However, little is known whether these stabilized oligomers are more or less toxic than α Syn aggregates formed in the absence of seeding with nitrated species. Figure 5.6A shows that Nseeded α Syn is more toxic than α Syn oligomers after twenty-four hours treatment in SY5Y cells. Indeed, investigations testing concentrations ranging from 0.5 to 4 μ M demonstrate that the toxicity elicited by Nseeded at 1-2 μ M is similar to that induced by 4 μ M non-seeded α Syn oligomers (Figure 5.6B). Similar results were observed in the Ca^{2+} imaging experiments (Figure 5.7), where 2 and 4 μ M Nseeded α Syn oligomers induced an immediate release of the intracellular fura-2 dye from SY5Y cells, thus suggesting that prompt cell membrane damage had occurred. Indeed, the cells visualized using DIC microscopy ruptured and were no longer visible at the same time the Fura-2 fluorescence diffused in the media, further suggesting that membrane destabilization and cell death had been promptly elicited after the addition of 2-4 μ M Nseeded α Syn oligomers (data not shown).

This evidence of increased toxicity of α Syn oligomers formed through seeding with nitrated α Syn is highly significant to the yet unclear mechanisms underlying the etiology of α Syn neuropathology and the reported impact thereupon of oxidative/nitrative cell stress. Collectively these data suggest that an oxidative stress-promoted nitration even of a small fraction of the α Syn pool may seed the formation of exceptionally toxic oligomers from the unmodified α Syn pool. The resulting trinitrated α Syn-seeded α Syn oligomers would be more stable than non-seeded α Syn aggregates and would not as quickly be detoxified by further aggregation into fibrils. This scenario would result in profound neurotoxicity, especially in those neurons whose metabolism is prone to generate high ambient levels of free radicals such as the dopaminergic neurons in the substantia nigra, one of the CNS regions most vulnerable in PD.

Chapter 6: Conclusion

This project focuses on underlying molecular events in synucleinopathies such as PD and DLB that involve toxic oligomeric assemblies of α Syn. Specifically, this project provides evidence for a novel pathway centered on CaN hyperactivation and concomitant CREB dephosphorylation, linking α Syn oligomers with synaptic dysfunction. Furthermore, this project demonstrates an association between synucleinopathies and oxidative/nitrative stress. Even though these two molecular events of oxidative/nitrative stress and synaptic dysfunction in synucleinopathies are separate, they have a compelling association that could be key to synucleinogenesis.

Like other disordered proteins, α Syn changes conformation relative to its environment. For instance, during pathological amyloidogenesis α Syn transitions conformation into a β -pleat structure followed by nucleation-dependent aggregation whereas the oligomeric species are the most toxic. One key mechanism of toxicity is

membrane destabilization resulting in ion dyshomeostasis such as increased Ca^{2+} (Lashuel, Hartley et al. 2002; Kaye, Head et al. 2003; Zhu, Li et al. 2003; Demuro, Mina et al. 2005; Glabe and Kaye 2006), but the downstream effects are not fully understood. Work previously done in our and our collaborators' laboratories have shown that oligomeric αSyn causes an increase in intracellular Ca^{2+} , CaN activation, decrease in pCREB, abolished LTP expression, and impaired memory in a CaN-dependent fashion *in vitro*, *ex vivo*, and *in vivo*. Notably, these intracellular signaling events were elicited from extracellularly applied αSyn . From the observation that αSyn oligomers cause an increase in intracellular Ca^{2+} , it is conceivable that these oligomers gain access to the cytosol through the membrane in order to elicit intracellular toxicity. This is complemented by studies revealing amyloid oligomer's ability to destabilize membranes through a pore-forming mechanism (Ding, Lee et al. 2002; Lashuel, Hartley et al. 2002; Lashuel, Petre et al. 2002; Kaye, Head et al. 2003; Zhu, Li et al. 2003; Demuro, Mina et al. 2005; Glabe and Kaye 2006). Evidence in human disease to show αSyn 's ability to bypass cell membranes is shown by αSyn 's presence in the CSF and plasma of PD patients (Borghi, Marchese et al. 2000; El-Agnaf, Salem et al. 2003) and fetal tissue grafted into the CNS of PD patients eventually developing αSyn aggregates (Kordower, Chu et al. 2008; Li, Englund et al. 2008).

To extend these findings of αSyn oligomer-elicited effects on intracellular signaling involving CaN activation and decreased pCREB to the actual diseased human brain, my project began by testing postmortem DLB frontal cortices compared to age-matched controls in which I discovered significantly higher levels of αSyn dimer, higher levels of truncated/active CaN, and lower levels of pCREB. In addition, I found that levels of the αSyn dimer had a significant negative correlation with pCREB levels. Similar to the *in vitro*, *ex vivo*, and *in vivo* evidence in Chapter 3, this evidence

demonstrated α Syn oligomers, through affecting proteins that are intimately involved in the control of synaptic plasticity, CaN and pCREB, may play a role in cognitive decline accompanying the progression of DLB, and possibly other synucleinopathies.

CaN activation was determined by measuring levels of the truncated subunit A, which is an event during CaN activation based on past literature (Liu, Grundke-Iqbal et al. 2005). I could not directly measure CaN activity in the brain samples because its enzymatic activity, regardless of disease state, was extremely low. It is known that loss of phosphatase activity is common in autopsy specimens where post-mortem oxidative deactivation of phosphatases cannot be prevented during cryopreservation (Wang, Culotta et al. 1996). Even though this approach is indirect, it complements the prior studies from Chapter 3 showing α Syn oligomer-induced and Ca^{2+} -mediated CaN activation *in vitro*, *ex vivo*, and *in vivo*. Moreover, CaN activation provides a connection between α Syn oligomers and decreased pCREB levels seen in postmortem DLB brains using Western blot and IHC. However, other factors could be at play as well, such as decreases in kinases but by evaluating the *in vitro*, *ex vivo*, and *in vivo* evidence in Chapter 3 with the human postmortem results in Chapter 4, it is prudent to conclude that CaN has an impact on pCREB levels in DLB brains. It is also notable that the dimer was the only oligomeric species that was significantly higher in DLB brains and had a significantly negative correlation with pCREB because recent literature evidence pertaining to the Alzheimer's amyloid-beta peptide points to the dimers as being the most toxic oligomers of this particular amyloid protein (Jin, Shepardson et al. ; Shankar, Li et al. 2008; Mc Donald, Savva et al. 2010). By using a variety of tools including cells, rodent brain slices, animal models, and postmortem tissue, it is more reliable to pinpoint exact mechanisms of disease pathology by first directing an answer to one question to

be tested through *in vitro*, *ex vivo*, and *in vivo* systems and then validating the scientific findings from the prior systems with examples in human disease.

However, biomedical research can also work in the opposite direction by making an observation in human disease and then testing mechanistic reasons on the bench. For example, synucleinopathies are synergistically associated with nitrative/oxidative stress but the mechanisms are not completely understood (Peng, Oo et al. ; Yu, Xu et al. ; Gao, Kotzbauer et al. 2008). With this in mind, the second half of my project was to determine structural and functional differences between nitrated and non-nitrated α Syn. Because α Syn is easily influenced by the environment, I first investigated structural differences of α Syn amyloid oligomers with nitrated α Syn and found using Western blot and AFM analyses that there are differences in conformations as shown by the differences in electrophoretic migrations rates on acrylamide gels and structural differences directly observed in the AFM images. Knowing that nitration causes covalent interactions, I challenged the nitrated α Syn species with β -sheet disrupters acetonitrile and HFIP. I observed that the nitrated α Syn species had increased resistance to such β -sheet disrupting treatments, suggesting the existence of inter-molecular covalent bonding. These results confirm prior literature stating nitrated α Syn demonstrates structural differences from α Syn oligomers resulting from covalent interactions (Souza, Giasson et al. 2000; Takahashi, Yamashita et al. 2002; Ruf, Lutz et al. 2008).

I also found functional differences between α Syn oligomers and the nitrated species, such as the nitrated species causing no immediate increase in intracellular Ca^{2+} , shortened LTP expression, and had no effect on pCREB levels, whereas α Syn oligomers increased intracellular Ca^{2+} , abolished LTP expression and decreased pCREB. However, the nitrated species did decrease cell viability after twenty-four hours treatment, suggesting that their toxicity may be exerted through a mechanism that does

not immediately involve membrane destabilization and abolishment of LTP expression. One possible explanation is that the nitration efficiency of the samples is not complete, and the non-nitrated α Syn portion in the sample could be seeded by the nitrated portion to form trace amounts of exceptionally toxic oligomers. Going with the idea of inter-seeding of the nitrated samples, it is probable that the time frame used in the present experiments was not long enough to observe effects on CREB dephosphorylation since this event is downstream of oligomer-induced decreased LTP expression. Currently, it cannot be excluded that pCREB might reduce in time in response to the treatment with nitrated α Syn species which may contain trace concentration of potentially seeded α Syn oligomers. Further studies should be done after isolation of nitrated α Syn from potentially non-nitrated α Syn using affinity chromatography to ensure purity of the samples.

The idea of nitrated α Syn influencing non-nitrated α Syn structure and function was first derived by studies demonstrating nitrated α Syn seeding α Syn resulting in stable oligomers and inhibition of fibril formation (Zhou, Long et al. ; Yamin, Uversky et al. 2003; Uversky, Yamin et al. 2005). To continue the investigation of the impact of nitrative modification in α Syn pathology, experiments using nitrated α Syn to seed α Syn (Nseeded) at a (1:10) stoichiometric ratio and stirred for five days were done to compare structural and functional differences of the seeded species with non-seeded α Syn. Western blot and AFM analyses revealed Nseeded results in oligomeric species but not fibrils, confirming prior studies showing that fibrillation is inhibited in Nseeded (Yamin, Uversky et al. 2003).

Cell viability studies revealed Nseeded is more toxic than α Syn oligomers. Indeed, investigations testing concentrations ranging from 0.5 to 4 μ M demonstrates toxicity between 1 and 2 μ M Nseeded being similar to that elicited by 4 μ M non-seeded α Syn oligomers. Similar results were obtained in Ca^{2+} imaging experiments. These

concentration ranges from both the cell viability and Ca^{2+} imaging experiments suggest Nseeded αSyn having greater toxicity than non-seeded αSyn oligomers. Moreover, these observations provide a molecular link between synucleinopathies and oxidative/nitrative stress.

My project will impact future studies in a two-pronged approach. The pathological mechanisms involving CaN could be an effective target for pharmacological inhibition of neuronal damage brought about by aggregating αSyn in human diseases. By halting the downstream signaling caused by increased intracellular Ca^{2+} at the point of CaN inhibition could rescue synaptic dysfunction and cognitive impairment. In addition, the evidence of seeding by nitrated αSyn of exceptionally toxic αSyn oligomers is compelling because oxidative/nitrative stress has been consistently described as part of the multifaceted mechanisms contributing to synucleinopathic human diseases. The evidence provided by my novel observations suggests a scenario whereby an individual with no CNS synuclein pathology but exposed to increased oxidative stress such as due to an inflammatory or chemical insult, could be challenged by a detrimental cascade of nitrative modifications of normal αSyn monomers resulting in profound seeding effects on the unmodified αSyn pool potentially resulting in triggering clinical synuclein pathology. Therefore, based on the results of my doctorate dissertation presented here, I propose that these collective mechanisms should be further considered in future studies as a valid target for the development of effective treatment strategies to halt or reverse αSyn -driven neuropathology in human diseases.

Bibliography

- Abeliovich, A., Y. Schmitz, et al. (2000). "Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system." Neuron 25(1): 239-52.
- Abraham, R. T. and G. J. Wiederrecht (1996). "Immunopharmacology of rapamycin." Annu Rev Immunol 14: 483-510.
- Ahn, B. H., H. Rhim, et al. (2002). "alpha-Synuclein interacts with phospholipase D isozymes and inhibits pervanadate-induced phospholipase D activation in human embryonic kidney-293 cells." J Biol Chem 277(14): 12334-42.
- Alberts, A. S., M. Montminy, et al. (1994). "Expression of a peptide inhibitor of protein phosphatase 1 increases phosphorylation and activity of CREB in NIH 3T3 fibroblasts." Mol Cell Biol 14(7): 4398-407.
- Angot, E., J. A. Steiner, et al. (2010). "Are synucleinopathies prion-like disorders?" Lancet Neurol 9(11): 1128-38.
- Baba, M., S. Nakajo, et al. (1998). "Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies." Am J Pathol 152(4): 879-84.
- Barnes, C. A. (1995). "Involvement of LTP in memory: are we "searching under the street light"?" Neuron 15(4): 751-4.
- Bear, M. F. (1995). "Mechanism for a sliding synaptic modification threshold." Neuron 15(1): 1-4.
- Belmeguenai, A. and C. Hansel (2005). "A role for protein phosphatases 1, 2A, and 2B in cerebellar long-term potentiation." J Neurosci 25(46): 10768-72.
- Bertoncini, C. W., Y. S. Jung, et al. (2005). "Release of long-range tertiary interactions potentiates aggregation of natively unstructured alpha-synuclein." Proc Natl Acad Sci U S A 102(5): 1430-5.
- Bhak, G., Y. J. Choe, et al. (2009). "Mechanism of amyloidogenesis: nucleation-dependent fibrillation versus double-concerted fibrillation." BMB Rep 42(9): 541-51.
- Bito, H., K. Deisseroth, et al. (1996). "CREB phosphorylation and dephosphorylation: a Ca(2+)- and stimulus duration-dependent switch for hippocampal gene expression." Cell 87(7): 1203-14.
- Borghini, R., R. Marchese, et al. (2000). "Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects." Neurosci Lett 287(1): 65-7.
- Bosco, D. A., D. M. Fowler, et al. (2006). "Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate alpha-synuclein fibrilization." Nat Chem Biol 2(5): 249-53.

- Braak, H. and K. Del Tredici (2008). "Invited Article: Nervous system pathology in sporadic Parkinson disease." Neurology 70(20): 1916-25.
- Braak, H., K. Del Tredici, et al. (2003). "Staging of brain pathology related to sporadic Parkinson's disease." Neurobiol Aging 24(2): 197-211.
- Braak, H., U. Rub, et al. (2005). "Cognitive status correlates with neuropathologic stage in Parkinson disease." Neurology 64(8): 1404-10.
- Braak, H., D. Sandmann-Keil, et al. (1999). "Extensive axonal Lewy neurites in Parkinson's disease: a novel pathological feature revealed by alpha-synuclein immunocytochemistry." Neurosci Lett 265(1): 67-9.
- Brown, D. R. (2010). "Oligomeric alpha-synuclein and its role in neuronal death." IUBMB Life 62(5): 334-9.
- Brown, H. A., L. G. Henage, et al. (2007). "Biochemical analysis of phospholipase D." Methods Enzymol 434: 49-87.
- Brundin, P., J. Y. Li, et al. (2008). "Research in motion: the enigma of Parkinson's disease pathology spread." Nat Rev Neurosci 9(10): 741-5.
- Brundin, P., R. Melki, et al. (2010). "Prion-like transmission of protein aggregates in neurodegenerative diseases." Nat Rev Mol Cell Biol 11(4): 301-7.
- Burn, D. J. and I. G. McKeith (2003). "Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease." Mov Disord 18 Suppl 6: S72-9.
- Burre, J., M. Sharma, et al. (2010). "Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro." Science 329(5999): 1663-7.
- Bussell, R., Jr. and D. Eliezer (2001). "Residual structure and dynamics in Parkinson's disease-associated mutants of alpha-synuclein." J Biol Chem 276(49): 45996-6003.
- Butcher, S. P., D. C. Henshall, et al. (1997). "Neuroprotective actions of FK506 in experimental stroke: in vivo evidence against an antiexcitotoxic mechanism." J Neurosci 17(18): 6939-46.
- Butterfield, S. M. and H. A. Lashuel "Amyloidogenic protein-membrane interactions: mechanistic insight from model systems." Angew Chem Int Ed Engl 49(33): 5628-54.
- Cabin, D. E., K. Shimazu, et al. (2002). "Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein." J Neurosci 22(20): 8797-807.
- Caviness, J. N., L. Lue, et al. (2011). "Parkinson's disease dementia and potential therapeutic strategies." CNS Neurosci Ther 17(1): 32-44.

- Chen, M., M. Margittai, et al. (2007). "Investigation of alpha-synuclein fibril structure by site-directed spin labeling." J Biol Chem 282(34): 24970-9.
- Choi, D. Y., M. Liu, et al. (2009). "Striatal neuroinflammation promotes Parkinsonism in rats." PLoS One 4(5): e5482.
- Choi, D. Y., J. Zhang, et al. "Aging enhances the neuroinflammatory response and alpha-synuclein nitration in rats." Neurobiol Aging 31(9): 1649-53.
- Chu, Y. and J. H. Kordower (2009). "Lewy body pathology in fetal grafts." Ann N Y Acad Sci 1184: 55-67.
- Clark, W. G., C. A. Vivonia, et al. (1968). "Accurate freehand injection into the lateral brain ventricle of the conscious mouse." J Appl Physiol 25(3): 319-21.
- Clayton, D. F. and J. M. George (1999). "Synucleins in synaptic plasticity and neurodegenerative disorders." J Neurosci Res 58(1): 120-9.
- Conway, K. A., J. D. Harper, et al. (2000). "Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid." Biochemistry 39(10): 2552-63.
- Conway, K. A., S. J. Lee, et al. (2000). "Accelerated oligomerization by Parkinson's disease linked alpha-synuclein mutants." Ann N Y Acad Sci 920: 42-5.
- Conway, K. A., J. C. Rochet, et al. (2001). "Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct." Science 294(5545): 1346-9.
- Dalfo, E., M. Portero-Otin, et al. (2005). "Evidence of oxidative stress in the neocortex in incidental Lewy body disease." J Neuropathol Exp Neurol 64(9): 816-30.
- Dauer, W. and S. Przedborski (2003). "Parkinson's disease: mechanisms and models." Neuron 39(6): 889-909.
- Dedmon, M. M., K. Lindorff-Larsen, et al. (2005). "Mapping long-range interactions in alpha-synuclein using spin-label NMR and ensemble molecular dynamics simulations." J Am Chem Soc 127(2): 476-7.
- Demuro, A., E. Mina, et al. (2005). "Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers." J Biol Chem 280(17): 17294-300.
- Desplats, P., H. J. Lee, et al. (2009). "Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein." Proc Natl Acad Sci U S A 106(31): 13010-5.
- Dineley, K. T., D. Hogan, et al. (2007). "Acute inhibition of calcineurin restores associative learning and memory in Tg2576 APP transgenic mice." Neurobiol Learn Mem.

- Dineley, K. T., R. Kayed, et al. (2010). "Amyloid-beta oligomers impair fear conditioned memory in a calcineurin-dependent fashion in mice." J Neurosci Res 88(13): 2923-32.
- Ding, T. T., S. J. Lee, et al. (2002). "Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes." Biochemistry 41(32): 10209-17.
- Dobson, C. M. (1999). "Protein misfolding, evolution and disease." Trends Biochem Sci 24(9): 329-32.
- Duda, J. E., B. I. Giasson, et al. (2000). "Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies." Am J Pathol 157(5): 1439-45.
- Duda, J. E., B. I. Giasson, et al. (2002). "Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases." Ann Neurol 52(2): 205-10.
- El-Agnaf, O. M., S. A. Salem, et al. (2003). "Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma." Faseb J 17(13): 1945-7.
- El-Agnaf, O. M., S. A. Salem, et al. (2006). "Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease." Faseb J 20(3): 419-25.
- Emmanouilidou, E., K. Melachroinou, et al. (2010). "Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival." J Neurosci 30(20): 6838-51.
- Emre, M. (2003). "Dementia associated with Parkinson's disease." Lancet Neurol 2(4): 229-37.
- Fernandez, C. O., W. Hoyer, et al. (2004). "NMR of alpha-synuclein-polyamine complexes elucidates the mechanism and kinetics of induced aggregation." EMBO J 23(10): 2039-46.
- Fink, A. L. (2006). "The aggregation and fibrillation of alpha-synuclein." Acc Chem Res 39(9): 628-34.
- Foster, T. C. (2007). "Calcium homeostasis and modulation of synaptic plasticity in the aged brain." Aging Cell 6(3): 319-25.
- Foster, T. C., K. M. Sharrow, et al. (2001). "Calcineurin links Ca²⁺ dysregulation with brain aging." J Neurosci 21(11): 4066-73.
- Fredenburg, R. A., C. Rospigliosi, et al. (2007). "The impact of the E46K mutation on the properties of alpha-synuclein in its monomeric and oligomeric states." Biochemistry 46(24): 7107-18.
- Freichel, C., M. Neumann, et al. (2007). "Age-dependent cognitive decline and amygdala pathology in alpha-synuclein transgenic mice." Neurobiol Aging 28(9): 1421-35.

- Fukudo, M., I. Yano, et al. (2005). "Distinct inhibitory effects of tacrolimus and cyclosporin a on calcineurin phosphatase activity." J Pharmacol Exp Ther 312(2): 816-25.
- Gajdusek, D. C. (1994). "Nucleation of amyloidogenesis in infectious and noninfectious amyloidoses of brain." Ann N Y Acad Sci 724: 173-90.
- Gao, H. M., P. T. Kotzbauer, et al. (2008). "Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration." J Neurosci 28(30): 7687-98.
- Gao, H. M., F. Zhang, et al. "Neuroinflammation and alpha-Synuclein Dysfunction Potentiate Each Other, Driving Chronic Progression of Neurodegeneration in a Mouse Model of Parkinson's Disease." Environ Health Perspect 119(6): 807-14.
- Gertz, H. J., A. Siegers, et al. (1994). "Stability of cell size and nucleolar size in Lewy body containing neurons of substantia nigra in Parkinson's disease." Brain Res 637(1-2): 339-41.
- Giasson, B. I., J. E. Duda, et al. (2000). "Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions." Science 290(5493): 985-9.
- Glabe, C. G. and R. Kaye (2006). "Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis." Neurology 66(2 Suppl 1): S74-8.
- Goedert, M. (2001). "Alpha-synuclein and neurodegenerative diseases." Nat Rev Neurosci 2(7): 492-501.
- Gomez-Tortosa, E., I. Gonzalo, et al. (2002). "Patterns of protein nitration in dementia with Lewy bodies and striatonigral degeneration." Acta Neuropathol 103(5): 495-500.
- Goosens, K. A. and S. Maren (2002). "Long-term potentiation as a substrate for memory: evidence from studies of amygdaloid plasticity and Pavlovian fear conditioning." Hippocampus 12(5): 592-9.
- Halpain, S., A. Hipolito, et al. (1998). "Regulation of F-actin stability in dendritic spines by glutamate receptors and calcineurin." J Neurosci 18(23): 9835-44.
- Hansen, C., E. Angot, et al. (2011). "alpha-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells." J Clin Invest 121(2): 715-25.
- Harper, J. D. and P. T. Lansbury, Jr. (1997). "Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins." Annu Rev Biochem 66: 385-407.
- Hashimoto, M. and E. Masliah (2003). "Cycles of aberrant synaptic sprouting and neurodegeneration in Alzheimer's and dementia with Lewy bodies." Neurochem Res 28(11): 1743-56.

- Hashimoto, M., E. Rockenstein, et al. (2001). "beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor." Neuron 32(2): 213-23.
- Hodara, R., E. H. Norris, et al. (2004). "Functional consequences of alpha-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation." J Biol Chem 279(46): 47746-53.
- Hotte, M., S. Thuaud, et al. (2007). "Phosphorylation of CREB and DARPP-32 during late LTP at hippocampal to prefrontal cortex synapses in vivo." Synapse 61(1): 24-8.
- Hotze, E. M., A. P. Heuck, et al. (2002). "Monomer-monomer interactions drive the prepore to pore conversion of a beta-barrel-forming cholesterol-dependent cytolysin." J Biol Chem 277(13): 11597-605.
- Howland, J. G. and Y. T. Wang (2008). "Synaptic plasticity in learning and memory: stress effects in the hippocampus." Prog Brain Res 169: 145-58.
- Hoyer, W., D. Cherny, et al. (2004). "Impact of the acidic C-terminal region comprising amino acids 109-140 on alpha-synuclein aggregation in vitro." Biochemistry 43(51): 16233-42.
- Huang, K. X. and H. K. Paudel (2000). "Ser67-phosphorylated inhibitor 1 is a potent protein phosphatase 1 inhibitor." Proc Natl Acad Sci U S A 97(11): 5824-9.
- Huie, R. E. and S. Padmaja (1993). "The reaction of NO with superoxide." Free Radic Res Commun 18(4): 195-9.
- Hurtig, H. I., J. Q. Trojanowski, et al. (2000). "Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease." Neurology 54(10): 1916-21.
- Jarrett, J. T. and P. T. Lansbury, Jr. (1993). "Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie?" Cell 73(6): 1055-8.
- Jenco, J. M., A. Rawlingson, et al. (1998). "Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins." Biochemistry 37(14): 4901-9.
- Jin, M., N. Shepardson, et al. "Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration." Proc Natl Acad Sci U S A 108(14): 5819-24.
- Jo, E., J. McLaurin, et al. (2000). "alpha-Synuclein membrane interactions and lipid specificity." J Biol Chem 275(44): 34328-34.
- Josselyn, S. A., S. Kida, et al. (2004). "Inducible repression of CREB function disrupts amygdala-dependent memory." Neurobiol Learn Mem 82(2): 159-63.
- Kahle, P. J. (2008). "alpha-Synucleinopathy models and human neuropathology: similarities and differences." Acta Neuropathol 115(1): 87-95.

- Kayed, R., E. Head, et al. (2003). "Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis." Science 300(5618): 486-9.
- Kayed, R., Y. Sokolov, et al. (2004). "Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases." J Biol Chem 279(45): 46363-6.
- Kinney, J. W., M. Sanchez-Alavez, et al. (2009). "Impairment of memory consolidation by galanin correlates with in vivo inhibition of both LTP and CREB phosphorylation." Neurobiol Learn Mem 92(3): 429-38.
- Kissinger, C. R., H. E. Parge, et al. (1995). "Crystal structures of human calcineurin and the human FKBP12-FK506-calcineurin complex." Nature 378(6557): 641-4.
- Kodali, R. and R. Wetzel (2007). "Polymorphism in the intermediates and products of amyloid assembly." Curr Opin Struct Biol 17(1): 48-57.
- Koppenol, W. H., J. J. Moreno, et al. (1992). "Peroxynitrite, a cloaked oxidant formed by nitric oxide and superoxide." Chem Res Toxicol 5(6): 834-42.
- Kordower, J. H., Y. Chu, et al. (2008). "Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease." Nat Med 14(5): 504-6.
- Kramer, M. L. and W. J. Schulz-Schaeffer (2007). "Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies." J Neurosci 27(6): 1405-10.
- Kruger, R., W. Kuhn, et al. (1998). "Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease." Nat Genet 18(2): 106-8.
- Larsen, K. E., Y. Schmitz, et al. (2006). "Alpha-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis." J Neurosci 26(46): 11915-22.
- Lashuel, H. A., D. Hartley, et al. (2002). "Neurodegenerative disease: amyloid pores from pathogenic mutations." Nature 418(6895): 291.
- Lashuel, H. A., B. M. Petre, et al. (2002). "Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils." J Mol Biol 322(5): 1089-102.
- Lee, H. J., S. Patel, et al. (2005). "Intravesicular localization and exocytosis of alpha-synuclein and its aggregates." J Neurosci 25(25): 6016-24.
- Lee, H. J., J. E. Suk, et al. (2010). "Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies." J Biol Chem 285(12): 9262-72.

- Lee, J., C. Jee, et al. (2004). "Opposing functions of calcineurin and CaMKII regulate G-protein signaling in egg-laying behavior of *C.elegans*." Journal of Molecular Biology 344(2): 585-95.
- Lee, S. J. (2008). "Origins and effects of extracellular alpha-synuclein: implications in Parkinson's disease." J Mol Neurosci 34(1): 17-22.
- Li, J. Y., E. Englund, et al. (2008). "Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation." Nat Med 14(5): 501-3.
- Li, W., N. West, et al. (2005). "Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations." Proc Natl Acad Sci U S A 102(6): 2162-7.
- Liu, F., I. Grundke-Iqbal, et al. (2005). "Truncation and activation of calcineurin A by calpain I in Alzheimer disease brain." J Biol Chem 280(45): 37755-62.
- Liu, Y. C. and D. R. Storm (1989). "Dephosphorylation of neuromodulin by calcineurin." J Biol Chem 264(22): 12800-4.
- Makin, O. S. and L. C. Serpell (2002). "Examining the structure of the mature amyloid fibril." Biochem Soc Trans 30(4): 521-5.
- Malleret, G., U. Haditsch, et al. (2001). "Inducible and reversible enhancement of learning, memory, and long-term potentiation by genetic inhibition of calcineurin." Cell 104(5): 675-86.
- Mansuy, I. M. (2003). "Calcineurin in memory and bidirectional plasticity." Biochem Biophys Res Commun 311(4): 1195-208.
- Mansuy, I. M., M. Mayford, et al. (1998). "Restricted and regulated overexpression reveals calcineurin as a key component in the transition from short-term to long-term memory." Cell 92(1): 39-49.
- Mansuy, I. M., D. G. Winder, et al. (1998). "Inducible and reversible gene expression with the rtTA system for the study of memory." Neuron 21(2): 257-65.
- Margittai, M. and R. Langen (2008). "Fibrils with parallel in-register structure constitute a major class of amyloid fibrils: molecular insights from electron paramagnetic resonance spectroscopy." Q Rev Biophys 41(3-4): 265-97.
- Maroteaux, L., J. T. Campanelli, et al. (1988). "Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal." Journal of Neuroscience 8(8): 2804-15.
- Martin, C. S. Z. (2009). "Therapeutic strategies against protein misfolding in neurodegenerative diseases." Expert Opinion on Drug Discovery 4(1): 71-84.
- Marui, W., E. Iseki, et al. (2002). "Progression and staging of Lewy pathology in brains from patients with dementia with Lewy bodies." J Neurol Sci 195(2): 153-9.

- Mattson, M. P. (2007). "Calcium and neurodegeneration." *Aging Cell* 6(3): 337-50.
- Mc Donald, J. M., G. M. Savva, et al. (2010). "The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia." *Brain* 133(Pt 5): 1328-41.
- McKeith, I. G., D. Galasko, et al. (1996). "Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop." *Neurology* 47(5): 1113-24.
- McNaught, K. S. and C. W. Olanow (2006). "Protein aggregation in the pathogenesis of familial and sporadic Parkinson's disease." *Neurobiol Aging* 27(4): 530-45.
- Mishizen-Eberz, A. J., E. H. Norris, et al. (2005). "Cleavage of alpha-synuclein by calpain: potential role in degradation of fibrillized and nitrated species of alpha-synuclein." *Biochemistry* 44(21): 7818-29.
- Morgan, C., M. Colombres, et al. (2004). "Structure and function of amyloid in Alzheimer's disease." *Prog Neurobiol* 74(6): 323-49.
- Mori, H., T. Kondo, et al. (1998). "Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q." *Neurology* 51(3): 890-2.
- Morishita, W., H. Marie, et al. (2005). "Distinct triggering and expression mechanisms underlie LTD of AMPA and NMDA synaptic responses." *Nat Neurosci* 8(8): 1043-50.
- Mulkey, R. M., S. Endo, et al. (1994). "Involvement of a calcineurin/inhibitor-1 phosphatase cascade in hippocampal long-term depression." *Nature* 369(6480): 486-8.
- Murphy, D. D., S. M. Rueter, et al. (2000). "Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons." *J Neurosci* 20(9): 3214-20.
- Ni, Z. and R. Chen (2008). "Repetitive transcranial magnetic stimulation: faster or longer is not necessarily more." *J Physiol* 586(16): 3733-4.
- Nishi, A., G. L. Snyder, et al. (1999). "Role of calcineurin and protein phosphatase-2A in the regulation of DARPP-32 dephosphorylation in neostriatal neurons." *J Neurochem* 72(5): 2015-21.
- Norris, E. H., B. I. Giasson, et al. (2003). "Effects of oxidative and nitrative challenges on alpha-synuclein fibrillogenesis involve distinct mechanisms of protein modifications." *J Biol Chem* 278(29): 27230-40.
- Olanow, C. W., D. P. Perl, et al. (2004). "Lewy-body formation is an aggresome-related process: a hypothesis." *Lancet Neurol* 3(8): 496-503.
- Osborne, B. M., J. J. Butler, et al. (1979). "Proteinaceous lymphadenopathy with hypergammaglobulinemia." *Am J Surg Pathol* 3(2): 137-45.

- Outeiro, T. F. and S. Lindquist (2003). "Yeast cells provide insight into alpha-synuclein biology and pathobiology." Science 302(5651): 1772-5.
- Paleologou, K. E., C. L. Kragh, et al. (2009). "Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies." Brain 132(Pt 4): 1093-101.
- Parihar, M. S., A. Parihar, et al. (2009). "Alpha-synuclein overexpression and aggregation exacerbates impairment of mitochondrial functions by augmenting oxidative stress in human neuroblastoma cells." Int J Biochem Cell Biol 41(10): 2015-24.
- Payton, J. E., R. J. Perrin, et al. (2004). "Structural determinants of PLD2 inhibition by alpha-synuclein." J Mol Biol 337(4): 1001-9.
- Peng, J., M. L. Oo, et al. "Synergistic effects of environmental risk factors and gene mutations in Parkinson's disease accelerate age-related neurodegeneration." J Neurochem 115(6): 1363-73.
- Pfeiffer, S., K. Schmidt, et al. (2000). "Dityrosine formation outcompetes tyrosine nitration at low steady-state concentrations of peroxynitrite. Implications for tyrosine modification by nitric oxide/superoxide in vivo." J Biol Chem 275(9): 6346-52.
- Pittenger, C. and E. Kandel (1998). "A genetic switch for long-term memory." C R Acad Sci III 321(2-3): 91-6.
- Polli, J. W., M. L. Billingsley, et al. (1991). "Expression of the calmodulin-dependent protein phosphatase, calcineurin, in rat brain: developmental patterns and the role of nigrostriatal innervation." Brain Res Dev Brain Res 63(1-2): 105-19.
- Polymeropoulos, M. H., C. Lavedan, et al. (1997). "Mutation in the alpha-synuclein gene identified in families with Parkinson's disease." Science 276(5321): 2045-7.
- Price, D. L., E. Rockenstein, et al. "Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic models of alpha-synucleinopathy--implications for excitotoxicity." PLoS One 5(11): e14020.
- Putcha, P., K. M. Danzer, et al. (2010). "Brain-permeable small-molecule inhibitors of Hsp90 prevent alpha-synuclein oligomer formation and rescue alpha-synuclein-induced toxicity." J Pharmacol Exp Ther 332(3): 849-57.
- Qin, Z., D. Hu, et al. (2007). "Effect of 4-hydroxy-2-nonenal modification on alpha-synuclein aggregation." J Biol Chem 282(8): 5862-70.
- Quist, A., I. Doudevski, et al. (2005). "Amyloid ion channels: a common structural link for protein-misfolding disease." Proc Natl Acad Sci U S A 102(30): 10427-32.
- Ramakers, G. M., K. Heinen, et al. (2000). "Long term depression in the CA1 field is associated with a transient decrease in pre- and postsynaptic PKC substrate phosphorylation." J Biol Chem 275(37): 28682-7.

- Reese, L. C., W. Zhang, et al. (2008). "Selective induction of calcineurin activity and signaling by oligomeric amyloid beta." *Aging Cell* 7(6): 824-35.
- Revuelta, G. J., A. Rosso, et al. (2008). "Neuritic pathology as a correlate of synaptic loss in dementia with lewy bodies." *Am J Alzheimers Dis Other Demen* 23(1): 97-102.
- Ruf, R. A., E. A. Lutz, et al. (2008). "Alpha-Synuclein conformation affects its tyrosine-dependent oxidative aggregation." *Biochemistry* 47(51): 13604-9.
- Sah, P., R. F. Westbrook, et al. (2008). "Fear conditioning and long-term potentiation in the amygdala: what really is the connection?" *Ann N Y Acad Sci* 1129: 88-95.
- Savitt, J. M., V. L. Dawson, et al. (2006). "Diagnosis and treatment of Parkinson disease: molecules to medicine." *J Clin Invest* 116(7): 1744-54.
- Schulz-Schaeffer, W. J. (2010). "The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia." *Acta Neuropathologica* 120(2): 131-43.
- Schulz, S., H. Siemer, et al. (1999). "Direct evidence for biphasic cAMP responsive element-binding protein phosphorylation during long-term potentiation in the rat dentate gyrus in vivo." *J Neurosci* 19(13): 5683-92.
- Seki, K., H. C. Chen, et al. (1995). "Dephosphorylation of protein kinase C substrates, neurogranin, neuromodulin, and MARCKS, by calcineurin and protein phosphatases 1 and 2A." *Arch Biochem Biophys* 316(2): 673-9.
- Serpell, L. C., J. Berriman, et al. (2000). "Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation." *Proc Natl Acad Sci U S A* 97(9): 4897-902.
- Serpell, L. C., M. Sunde, et al. (1997). "The molecular basis of amyloidosis." *Cell Mol Life Sci* 53(11-12): 871-87.
- Sevcsik, E., A. J. Trexler, et al. "Allostery in a disordered protein: oxidative modifications to alpha-synuclein act distally to regulate membrane binding." *J Am Chem Soc* 133(18): 7152-8.
- Shankar, G. M., S. Li, et al. (2008). "Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory." *Nature Medicine* 14(8): 837-42.
- Sharma, S. K., M. W. Bagnall, et al. (2003). "Inhibition of calcineurin facilitates the induction of memory for sensitization in Aplysia: requirement of mitogen-activated protein kinase." *Proc Natl Acad Sci U S A* 100(8): 4861-6.
- Sharon, R., I. Bar-Joseph, et al. (2003). "The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease." *Neuron* 37(4): 583-95.

- Shou, Y., L. Li, et al. (2004). "Calcineurin-mediated Bad translocation regulates cyanide-induced neuronal apoptosis." Biochem J 379(Pt 3): 805-13.
- Sik, A., N. Hajos, et al. (1998). "The absence of a major Ca²⁺ signaling pathway in GABAergic neurons of the hippocampus." Proc Natl Acad Sci U S A 95(6): 3245-50.
- Silva, A. J., J. H. Kogan, et al. (1998). "CREB and memory." Annu Rev Neurosci 21: 127-48.
- Smith, M. P. and W. A. Cass (2007). "Oxidative stress and dopamine depletion in an intrastriatal 6-hydroxydopamine model of Parkinson's disease." Neuroscience 144(3): 1057-66.
- Souza, J. M., B. I. Giasson, et al. (2000). "Dityrosine cross-linking promotes formation of stable alpha-synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies." J Biol Chem 275(24): 18344-9.
- Spillantini, M. G., R. A. Crowther, et al. (1998). "Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies." Neurosci Lett 251(3): 205-8.
- Springer, J. E., R. D. Azbill, et al. (2000). "Calcineurin-mediated BAD dephosphorylation activates the caspase-3 apoptotic cascade in traumatic spinal cord injury." J Neurosci 20(19): 7246-51.
- Stefan, M. I., S. J. Edelman, et al. (2008). "An allosteric model of calmodulin explains differential activation of PP2B and CaMKII." Proc Natl Acad Sci U S A 105(31): 10768-73.
- Takahashi, H., E. Ohama, et al. (1994). "Familial juvenile parkinsonism: clinical and pathologic study in a family." Neurology 44(3 Pt 1): 437-41.
- Takahashi, T., H. Yamashita, et al. (2002). "Tyrosine 125 of alpha-synuclein plays a critical role for dimerization following nitrative stress." Brain Res 938(1-2): 73-80.
- Thomas, A. J., D. J. Burn, et al. (2005). "A comparison of the efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies." Int J Geriatr Psychiatry 20(10): 938-44.
- Tompkins, M. M. and W. D. Hill (1997). "Contribution of somal Lewy bodies to neuronal death." Brain Res 775(1-2): 24-9.
- Trostchansky, A., S. Lind, et al. (2006). "Interaction with phospholipids modulates alpha-synuclein nitration and lipid-protein adduct formation." Biochem J 393(Pt 1): 343-9.
- Trostchansky, A. and H. Rubbo (2007). "Lipid nitration and formation of lipid-protein adducts: biological insights." Amino Acids 32(4): 517-22.
- Tsika, E., M. Moysidou, et al. "Distinct region-specific alpha-synuclein oligomers in A53T transgenic mice: implications for neurodegeneration." J Neurosci 30(9): 3409-18.

- Uversky, V. N. "Mysterious oligomerization of the amyloidogenic proteins." FEBS J 277(14): 2940-53.
- Uversky, V. N., J. Li, et al. (2001). "Evidence for a partially folded intermediate in alpha-synuclein fibril formation." J Biol Chem 276(14): 10737-44.
- Uversky, V. N., G. Yamin, et al. (2005). "Effects of nitration on the structure and aggregation of alpha-synuclein." Brain Res Mol Brain Res 134(1): 84-102.
- van Rooijen, B. D., M. M. Claessens, et al. (2009). "Lipid bilayer disruption by oligomeric alpha-synuclein depends on bilayer charge and accessibility of the hydrophobic core." Biochim Biophys Acta 1788(6): 1271-8.
- Volles, M. J. and P. T. Lansbury, Jr. (2002). "Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism." Biochemistry 41(14): 4595-602.
- Volles, M. J. and P. T. Lansbury, Jr. (2003). "Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease." Biochemistry 42(26): 7871-8.
- Wang, H. G., N. Pathan, et al. (1999). "Ca²⁺-induced apoptosis through calcineurin dephosphorylation of BAD." Science 284(5412): 339-43.
- Wang, X., V. C. Culotta, et al. (1996). "Superoxide dismutase protects calcineurin from inactivation." Nature 383(6599): 434-7.
- Weinreb, P. H., W. Zhen, et al. (1996). "NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded." Biochemistry 35(43): 13709-15.
- Wetzel, R., S. Shivaprasad, et al. (2007). "Plasticity of amyloid fibrils." Biochemistry 46(1): 1-10.
- White, B. C., J. M. Sullivan, et al. (2000). "Brain ischemia and reperfusion: molecular mechanisms of neuronal injury." Journal of the Neurological Sciences 179(S 1-2): 1-33.
- Winder, D. G., I. M. Mansuy, et al. (1998). "Genetic and pharmacological evidence for a novel, intermediate phase of long-term potentiation suppressed by calcineurin." Cell 92(1): 25-37.
- Winner, B., R. Jappelli, et al. (2011). "In vivo demonstration that alpha-synuclein oligomers are toxic." Proc Natl Acad Sci U S A 108(10): 4194-9.
- Wu, G. Y., K. Deisseroth, et al. (2001). "Activity-dependent CREB phosphorylation: convergence of a fast, sensitive calmodulin kinase pathway and a slow, less sensitive mitogen-activated protein kinase pathway." Proc Natl Acad Sci U S A 98(5): 2808-13.
- Yamin, G., V. N. Uversky, et al. (2003). "Nitration inhibits fibrillation of human alpha-synuclein in vitro by formation of soluble oligomers." FEBS Lett 542(1-3): 147-52.

- Yang, L., K. Omori, et al. (2004). "Calcineurin-mediated BAD Ser155 dephosphorylation in ammonia-induced apoptosis of cultured rat hippocampal neurons." Neurosci Lett 357(1): 73-5.
- Yoshiike, Y., R. Kayed, et al. (2007). "Pore-forming proteins share structural and functional homology with amyloid oligomers." Neuromolecular Med 9(3): 270-5.
- Yu, Z., X. Xu, et al. "Nitrated alpha-synuclein induces the loss of dopaminergic neurons in the substantia nigra of rats." PLoS One 5(4): e9956.
- Yuan, Y., J. Sun, et al. "Overexpression of alpha-synuclein down-regulates BDNF expression." Cell Mol Neurobiol 30(6): 939-46.
- Zaja-Milatovic, S., C. D. Keene, et al. (2006). "Selective dendritic degeneration of medium spiny neurons in dementia with Lewy bodies." Neurology 66(10): 1591-3.
- Zaja-Milatovic, S., D. Milatovic, et al. (2005). "Dendritic degeneration in neostriatal medium spiny neurons in Parkinson disease." Neurology 64(3): 545-7.
- Zarranz, J. J., J. Alegre, et al. (2004). "The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia." Ann Neurol 55(2): 164-73.
- Zeng, H., S. Chattarji, et al. (2001). "Forebrain-specific calcineurin knockout selectively impairs bidirectional synaptic plasticity and working/episodic-like memory." Cell 107(5): 617-29.
- Zhou, W., C. Long, et al. "Methionine oxidation stabilizes non-toxic oligomers of alpha-synuclein through strengthening the auto-inhibitory intra-molecular long-range interactions." Biochim Biophys Acta 1802(3): 322-30.
- Zhu, M., J. Li, et al. (2003). "The association of alpha-synuclein with membranes affects bilayer structure, stability, and fibril formation." J Biol Chem 278(41): 40186-97.

Vita

Zane S. Martin

7583 Amboy Road

Staten Island, NY 10307

Birthplace and Birthdate: August 28, 1975 in San Angelo, TX

Parents: Roy Martin and Suzanne Shurley Huddleston

Education:

B.S. Angelo State University , 2005

Biochemistry and Psychology

M.S. The University of Texas Medical Branch, 2008

Pharmacology

Ph.D. The University of Texas Medical Branch, 2011

Neuroscience

Publications:

Articles

Martin Z, Neugebauer V, Dineley K, Kaye R, Zhang W, Reese L, Tagliatella G. Alpha synuclein oligomers oppose long term potentiation and impair memory through a calcineurin-dependent mechanism: relevance to human synucleopathic diseases. *J. Neurochem.* In Press

Chen D*, **Martin Z***, Soto C, Schein C. Computational selection of inhibitors of Aβ aggregation and neuronal toxicity. *Bioorg Med Chem* 2009 Jul 15;17(14):5189-97. *first two authors contributed equally to this study

Martin-Jones, Z., Lasagna-Reeves, C. Which is a better target for AD immunotherapy, Aβ or Tau? *Alzheimer Disease & Associated Disorders* 2008 Apr-Jun;22(2):111-2.

Chapters and Reviews

Martin, Z., and Soto, C. (2010) **Anti-misfolding and anti-fibrillization therapies for Protein Misfolding Disorders.** Chapter in the book "*Protein Misfolding Diseases: Current and Emerging Principles and Therapies*", Ramirez-Alvarado, M., Kelly, J. and Dobson, C. (Eds). John Wiley and Sons, 933-944.

Soto, C., and **Martin, Z.** Therapeutic Strategies Against Protein Misfolding in Neurodegenerative Diseases. *Expert Op. Drug Disc.* (2009) 4 (1):71-84.

This dissertation was typed by Zane Martin.